
Chantal Mathieu

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4337553/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	The use of glucagon-like-peptide-1 receptor agonist in the cardiology practice. Acta Cardiologica, 2023, 78, 552-564.	0.9	2
2	Prevalence of Atherosclerotic Cardiovascular Disease, Heart Failure, and Chronic Kidney Disease in Patients with Type 2 Diabetes Mellitus: A Primary Care Research Network-based Study. Experimental and Clinical Endocrinology and Diabetes, 2022, 130, 447-453.	1.2	6
3	Cardiometabolic and Kidney Protection in Kidney Transplant Recipients With Diabetes: Mechanisms, Clinical Applications, and Summary of Clinical Trials. Transplantation, 2022, 106, 734-748.	1.0	6
4	Relationship Between Time in Range, Glycemic Variability, HbA1c, and Complications in Adults With Type 1 Diabetes Mellitus. Journal of Clinical Endocrinology and Metabolism, 2022, 107, e570-e581.	3.6	39
5	Pancreas Islet Cell-Specific Antibody Detection by ELISA. journal of applied laboratory medicine, The, 2022, 7, 66-74.	1.3	4
6	Fasting plasma glucose level to guide the need for an OGTT to screen for gestational diabetes mellitus. Acta Diabetologica, 2022, 59, 381-394.	2.5	5
7	Glycaemic management in diabetes: old and new approaches. Lancet Diabetes and Endocrinology,the, 2022, 10, 75-84.	11.4	50
8	Real-world Evidence of Efficacy and Safety of SGLT2 Inhibitors as Adjunctive Therapy in Adults With Type 1 Diabetes: A European Two-Center Experience. Diabetes Care, 2022, 45, 650-658.	8.6	29
9	Diabetes and the WHO Model List of Essential Medicines. Lancet Diabetes and Endocrinology,the, 2022, 10, 18-19.	11.4	3
10	Diabetic Ketoacidosis After Sodium–Glucose Cotransporter Inhibitor Initiation Under Advanced Hybrid Closed-Loop Therapy in Type 1 Diabetes. Diabetes Technology and Therapeutics, 2022, 24, 516-519.	4.4	4
11	Screening for Type 1 Diabetes in the General Population: A Status Report and Perspective. Diabetes, 2022, 71, 610-623.	0.6	59
12	Effects of repeated infections with non-typeable Haemophilus influenzae on lung in vitamin D deficient and smoking mice. Respiratory Research, 2022, 23, 40.	3.6	1
13	MO1037: Insulin Sensitivity in Children with Autosomal Dominant Polycystic Kidney Disease. Nephrology Dialysis Transplantation, 2022, 37, .	0.7	0
14	INNODIA Master Protocol for the evaluation of investigational medicinal products in children, adolescents and adults with newly diagnosed type 1 diabetes. Trials, 2022, 23, 414.	1.6	12
15	Predictors of time in target glucose range in realâ€world users of the <scp>MiniMed 780G</scp> system. Diabetes, Obesity and Metabolism, 2022, 24, 2212-2221.	4.4	44
16	<scp>Longâ€ŧerm</scp> efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes: pooled <scp>52â€week</scp> outcomes from the <scp>DEPICT</scp> â€1 and â€2 studies. Diabetes, Obesity and Metabolism, 2021, 23, 549-560.	4.4	21
17	A randomised, single-blind, placebo-controlled, dose-finding safety and tolerability study of the anti-CD3 monoclonal antibody otelixizumab in new-onset type 1 diabetes. Diabetologia, 2021, 64, 313-324.	6.3	27
18	Guideline recommendations and the positioning of newer drugs in type 2 diabetes care. Lancet Diabetes and Endocrinology,the, 2021, 9, 46-52.	11.4	103

#	Article	IF	CITATIONS
19	Improving the treatment of patients with diabetes using insulin analogues: current findings and future directions. Expert Opinion on Drug Safety, 2021, 20, 155-169.	2.4	8
20	Predictors of neonatal adiposity and associations by fetal sex in women with gestational diabetes mellitus and normal glucose-tolerant women. Acta Diabetologica, 2021, 58, 341-354.	2.5	4
21	Women with Mild Fasting Hyperglycemia in Early Pregnancy Have More Neonatal Intensive Care Admissions. Journal of Clinical Endocrinology and Metabolism, 2021, 106, e836-e854.	3.6	11
22	Peptidylarginine Deiminase Inhibition Prevents Diabetes Development in NOD Mice. Diabetes, 2021, 70, 516-528.	0.6	25
23	Early combination therapy delayed treatment escalation in newly diagnosed youngâ€onset type 2 diabetes: A subanalysis of the <scp>VERIFY</scp> study. Diabetes, Obesity and Metabolism, 2021, 23, 245-251.	4.4	13
24	Twenty-Four Hour Fasting (Basal Rate) Tests to Achieve Custom-Tailored, Hour-by-Hour Basal Insulin Infusion Rates in Patients With Type 1 Diabetes Using Insulin Pumps (CSII). Journal of Diabetes Science and Technology, 2021, 15, 360-370.	2.2	12
25	Minimising hypoglycaemia in the real world: the challenge of insulin. Diabetologia, 2021, 64, 978-984.	6.3	5
26	Glucose management for exercise using continuous glucose monitoring: should sex and prandial state be additional considerations? Reply to Yardley JE and Sigal RJ [letter]. Diabetologia, 2021, 64, 935-938.	6.3	4
27	Antenatal Depression and Risk of Gestational Diabetes, Adverse Pregnancy Outcomes, and Postpartum Quality of Life. Journal of Clinical Endocrinology and Metabolism, 2021, 106, e3110-e3124.	3.6	20
28	Longâ€term (52â€week) efficacy and safety of dapagliflozin as an adjunct to insulin therapy in Japanese patients with type 1 diabetes: Subgroup analysis of the <scp>DEPICT</scp> â€2 study. Diabetes, Obesity and Metabolism, 2021, 23, 1496-1504.	4.4	6
29	Diabetes Knowledge and Metabolic Control in Type 1 Diabetes Starting With Continuous Glucose Monitoring: FUTURE-PEAK. Journal of Clinical Endocrinology and Metabolism, 2021, 106, e3037-e3048.	3.6	10
30	Fat Induces Glucose Metabolism in Nontransformed Liver Cells and Promotes Liver Tumorigenesis. Cancer Research, 2021, 81, 1988-2001.	0.9	43
31	Positioning newer drugs in the management of type 2 diabetes. Lancet Diabetes and Endocrinology,the, 2021, 9, 139-140.	11.4	3
32	A Randomized, Open-Label Comparison of Once-Weekly Insulin Icodec Titration Strategies Versus Once-Daily Insulin Glargine U100. Diabetes Care, 2021, 44, 1595-1603.	8.6	41
33	Anti-interleukin-21 antibody and liraglutide for the preservation of β-cell function in adults with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Diabetes and Endocrinology,the, 2021, 9, 212-224.	11.4	85
34	Targeting citrullination in autoimmunity: insights learned from preclinical mouse models. Expert Opinion on Therapeutic Targets, 2021, 25, 269-281.	3.4	10
35	100 YEARS OF INSULIN: Arresting or curing type 1 diabetes: an elusive goal, but closing the gap. Journal of Endocrinology, 2021, 249, T1-T11.	2.6	4
36	162-LB: Plasma Glycated CD59 Predicts Postpartum Glucose Intolerance after Gestational Diabetes. Diabetes, 2021, 70, .	0.6	0

#	Article	IF	CITATIONS
37	726-P: Glucose Control Using Fast-Acting Insulin Aspart in a Real-World Setting: A One-Year Multicenter Study in People with Type 1 Diabetes Using Continuous Glucose Monitoring. Diabetes, 2021, 70, 726-P.	0.6	0
38	Exploring early combination strategy in Latin American patients with newly diagnosed type 2 diabetes: a sub-analysis of the VERIFY study. Diabetology and Metabolic Syndrome, 2021, 13, 68.	2.7	0
39	Comparing real-time and intermittently scanned continuous glucose monitoring in adults with type 1 diabetes (ALERTT1): a 6-month, prospective, multicentre, randomised controlled trial. Lancet, The, 2021, 397, 2275-2283.	13.7	100
40	Type 1 diabetes glycemic management: Insulin therapy, glucose monitoring, and automation. Science, 2021, 373, 522-527.	12.6	43
41	Adnexectomy by vaginal Natural Orifice Transluminal Endoscopic Surgery versus laparoscopy: results of a first randomised controlled trial (NOTABLE trial). BJOG: an International Journal of Obstetrics and Gynaecology, 2021, 128, 1782-1791.	2.3	32
42	Glucose control using fastâ€acting insulin aspart in a realâ€world setting: A <scp>1</scp> â€year, twoâ€centre study in people with type <scp>1</scp> diabetes using continuous glucose monitoring. Diabetes, Obesity and Metabolism, 2021, 23, 2716-2727.	4.4	11
43	One hundred years of insulin therapy. Nature Reviews Endocrinology, 2021, 17, 715-725.	9.6	49
44	Effect of an Integrated, Multidisciplinary Nationwide Approach to Type 1 Diabetes Care on Metabolic Outcomes: An Observational Real-World Study. Diabetes Technology and Therapeutics, 2021, 23, 565-576.	4.4	16
45	Plasma glycated CD59 predicts postpartum glucose intolerance after gestational diabetes. European Journal of Endocrinology, 2021, 185, 755-763.	3.7	2
46	Obesity in people living with type 1 diabetes. Lancet Diabetes and Endocrinology,the, 2021, 9, 776-785.	11.4	49
47	Efficacy and safety of liraglutide in type 1 diabetes by baseline characteristics in the <scp>ADJUNCT ONE</scp> and <scp>ADJUNCT TWO</scp> randomized controlled trials. Diabetes, Obesity and Metabolism, 2021, 23, 2752-2762.	4.4	16
48	Protocol to analyze circulating small non-coding RNAs by high-throughput RNA sequencing from human plasma samples. STAR Protocols, 2021, 2, 100606.	1.2	7
49	Defining a cure for type 1 diabetes: a call to action. Lancet Diabetes and Endocrinology,the, 2021, 9, 553-555.	11.4	12
50	CD8+ T cells variably recognize native versus citrullinated GRP78 epitopes in type 1 diabetes. Diabetes, 2021, 70, db210259.	0.6	11
51	Seroprevalence of Antibodies against Diphtheria, Tetanus and Pertussis in Adult At-Risk Patients. Vaccines, 2021, 9, 18.	4.4	7
52	Identification of Deamidated Peptides in Cytokine-Exposed MIN6 Cells through LCâ^'MS/MS Using a Shortened Digestion Time and Inspection of MS2 Spectra. Journal of Proteome Research, 2021, 20, 1405-1414.	3.7	6
53	Advances in newer basal and bolus insulins: impact on type 1 diabetes. Current Opinion in Endocrinology, Diabetes and Obesity, 2021, 28, 1-7.	2.3	13
54	Use of Metformin and Cardiovascular Effects of New Classes of Glucose-Lowering Agents: A Meta-analysis of Cardiovascular Outcome Trials in Type 2 Diabetes. Diabetes Care, 2021, 44, e32-e34.	8.6	12

#	Article	IF	CITATIONS
55	Risk for ketonaemia in type 1 diabetes pregnancies with sensor-augmented pump therapy with predictive low glucose suspend compared with low glucose suspend: a crossover RCT. Diabetologia, 2021, 64, 2725-2730.	6.3	3
56	COVID-19, Hyperglycemia, and New-Onset Diabetes. Diabetes Care, 2021, 44, 2645-2655.	8.6	164
57	Preference of Women for Gestational Diabetes Screening Method According to Tolerance of Tests and Population Characteristics. Frontiers in Endocrinology, 2021, 12, 781384.	3.5	4
58	Are newer insulin analogues better for people with Type 1 diabetes?. Diabetic Medicine, 2020, 37, 522-531.	2.3	7
59	The 2019 Flemish consensus on screening for overt diabetes in early pregnancy and screening for gestational diabetes mellitus. Acta Clinica Belgica, 2020, 75, 340-347.	1.2	16
60	miR-409-3p is reduced in plasma and islet immune infiltrates of NOD diabetic mice and is differentially expressed in people with type 1 diabetes. Diabetologia, 2020, 63, 124-136.	6.3	23
61	Estimating the risk of gestational diabetes mellitus based on the 2013 WHO criteria: a prediction model based on clinical and biochemical variables in early pregnancy. Acta Diabetologica, 2020, 57, 661-671.	2.5	31
62	2019 update to: Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia, 2020, 63, 221-228.	6.3	368
63	2019 Update to: Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care, 2020, 43, 487-493.	8.6	846
64	Quality of Life and Glucose Control After 1 Year of Nationwide Reimbursement of Intermittently Scanned Continuous Glucose Monitoring in Adults Living With Type 1 Diabetes (FUTURE): A Prospective Observational Real-World Cohort Study. Diabetes Care, 2020, 43, 389-397.	8.6	163
65	Intermittently scanned continuous glucose monitoring is associated with high satisfaction but increased HbA1c and weight in wellâ€controlled youth with type 1 diabetes. Pediatric Diabetes, 2020, 21, 1465-1474.	2.9	8
66	Sustained Impact of Real-time Continuous Glucose Monitoring in Adults With Type 1 Diabetes on Insulin Pump Therapy: Results After the 24-Month RESCUE Study. Diabetes Care, 2020, 43, 3016-3023.	8.6	28
67	Use of Culture to Reach Metabolically Adequate Beta-cell Dose by Combining Donor Islet Cell Isolates for Transplantation in Type 1 Diabetes Patients. Transplantation, 2020, 104, e295-e302.	1.0	1
68	Insights from VERIFY: Early Combination Therapy Provides Better Glycaemic Durability Than a Stepwise Approach in Newly Diagnosed TypeÂ2 Diabetes. Diabetes Therapy, 2020, 11, 2465-2476.	2.5	15
69	Pancreatic Alpha-Cells Contribute Together With Beta-Cells to CXCL10 Expression in Type 1 Diabetes. Frontiers in Endocrinology, 2020, 11, 630.	3.5	17
70	Glucose management for exercise using continuous glucose monitoring (CGM) and intermittently scanned CGM (isCGM) systems in type 1 diabetes: position statement of the European Association for the Study of Diabetes (EASD) and of the International Society for Pediatric and Adolescent Diabetes (ISPAD) endorsed by JDRF and supported by the American Diabetes Association (ADA). Diabetologia, 2020,	6.3	102
71	Glucose Internet for exercise using continuous glucose monitoring (<scp>CGW(</scp>) and intermittently scanned <scp>CGM</scp> (<scp>isCGM</scp>) systems in type 1 diabetes: position statement of the European Association for the Study of Diabetes (<scp>EASD</scp>) and of the International Society for Pediatric and Adolescent Diabetes (<scp>ISPAD</scp>) endorsed by <scp>.</scp>	2.9	46
72	Vaccination coverage of recommended vaccines and determinants of vaccination in at-risk groups. Human Vaccines and Immunotherapeutics, 2020, 16, 2136-2143.	3.3	32

#	Article	IF	CITATIONS
73	No Evidence of Increased Hospitalization Rate for COVID-19 in Community-Dwelling Patients With Type 1 Diabetes. Diabetes Care, 2020, 43, e118-e119.	8.6	24
74	How GDPR Enhances Transparency and Fosters Pseudonymisation in Academic Medical Research. European Journal of Health Law, 2020, 27, 35-57.	0.2	3
75	SARS-CoV-2 Receptor Angiotensin I-Converting Enzyme Type 2 (ACE2) Is Expressed in Human Pancreatic β-Cells and in the Human Pancreas Microvasculature. Frontiers in Endocrinology, 2020, 11, 596898.	3.5	144
76	Benefit/risk profile of dapagliflozin 5 mg in the <scp>DEPICT</scp> â€1 and â€2 trials in individuals with type 1 diabetes and body mass index ≥27 kg/m ² . Diabetes, Obesity and Metabolism, 2020, 2151-2160.	22,4	23
77	Differential Proteomic Analysis of Hepatocellular Carcinomas from <i>Ppp2r5d</i> Knockout Mice and Normal (Knockout) Livers. Cancer Genomics and Proteomics, 2020, 17, 669-685.	2.0	5
78	Mobile-Based Lifestyle Intervention in Women with Glucose Intolerance after Gestational Diabetes Mellitus (MELINDA), A Multicenter Randomized Controlled Trial: Methodology and Design. Journal of Clinical Medicine, 2020, 9, 2635.	2.4	5
79	Effect of dapagliflozin as an adjunct to insulin over 52 weeks in individuals with type 1 diabetes: post-hoc renal analysis of the DEPICT randomised controlled trials. Lancet Diabetes and Endocrinology,the, 2020, 8, 845-854.	11.4	46
80	SGLT inhibitors in type 1 diabetes: weighing efficacy and side effects. Therapeutic Advances in Endocrinology and Metabolism, 2020, 11, 204201882093854.	3.2	15
81	Positioning sulphonylureas in a modern treatment algorithm for patients with type 2 diabetes: Expert opinion from a European consensus panel. Diabetes, Obesity and Metabolism, 2020, 22, 1705-1713.	4.4	17
82	Intestinal Delivery of Proinsulin and IL-10 via Lactococcus lactis Combined With Low-Dose Anti-CD3 Restores Tolerance Outside the Window of Acute Type 1 Diabetes Diagnosis. Frontiers in Immunology, 2020, 11, 1103.	4.8	19
83	Multidisciplinary Group Education for Gestational Diabetes Mellitus: A Prospective Observational Cohort Study. Journal of Clinical Medicine, 2020, 9, 509.	2.4	9
84	Impact of Switching from Twice-Daily Basal Insulin to Once-Daily Insulin Glargine 300ÂU/mL in People with TypeÂ1 Diabetes on Basal–Bolus Insulin: PhaseÂ4 OPTIMIZE Study. Diabetes Therapy, 2020, 11, 495-507.	2.5	3
85	Vitamin D's Effect on Immune Function. Nutrients, 2020, 12, 1248.	4.1	231
86	Effect of Intravenous 25OHD Supplementation on Bone Turnover and Inflammation in Prolonged Critically III Patients. Hormone and Metabolic Research, 2020, 52, 168-178.	1.5	8
87	Longâ€ŧerm efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (the <scp>DEPICT</scp> â€2 study): 52â€week results from a randomized controlled trial. Diabetes, Obesity and Metabolism, 2020, 22, 1516-1526.	4.4	38
88	278-OR: Efficacy and Safety of Anti-interleukin (IL)-21 in Combination with Liraglutide in Adults Recently Diagnosed with Type 1 Diabetes. Diabetes, 2020, 69, .	0.6	1
89	94-LB: Long-Term Clinical Benefits of Early Combination Approach in Latin American Subpopulation of VERIFY Study. Diabetes, 2020, 69, 94-LB.	0.6	0
90	Fostering improved human islet research: a European perspective. Diabetologia, 2019, 62, 1514-1516.	6.3	13

#	Article	IF	CITATIONS
91	Characteristics and pregnancy outcomes across gestational diabetes mellitus subtypes based on insulin resistance. Diabetologia, 2019, 62, 2118-2128.	6.3	87
92	<p>Empagliflozin in type 1 diabetes</p> . Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 2019, Volume 12, 1555-1561.	2.4	8
93	Age-Dependent Changes in Glucose Homeostasis in Male Deiodinase Type 2 Knockout Zebrafish. Endocrinology, 2019, 160, 2759-2772.	2.8	8
94	The Risk for Glucose Intolerance after Gestational Diabetes Mellitus since the Introduction of the IADPSG Criteria: A Systematic Review and Meta-Analysis. Journal of Clinical Medicine, 2019, 8, 1431.	2.4	30
95	Oral insulin: time to rewrite the textbooks. Lancet Diabetes and Endocrinology,the, 2019, 7, 162-163.	11.4	10
96	Exploring Patient Preferences for Adjunct-to-Insulin Therapy in Type 1 Diabetes. Diabetes Care, 2019, 42, 1716-1723.	8.6	10
97	Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From the International Consensus on Time in Range. Diabetes Care, 2019, 42, 1593-1603.	8.6	2,101
98	Use of fastâ€acting insulin aspart in insulin pump therapy in clinical practice. Diabetes, Obesity and Metabolism, 2019, 21, 2039-2047.	4.4	41
99	Authors' reply re: Hysterectomy by transvaginal natural orifice transluminal endoscopic surgery versus laparoscopy as a daycare procedure: a randomised controlled trial. BJOG: an International Journal of Obstetrics and Gynaecology, 2019, 126, 1078-1079.	2.3	1
100	Prediction of Glucose Intolerance in Early Postpartum in Women with Gestational Diabetes Mellitus Based on the 2013 WHO Criteria. Journal of Clinical Medicine, 2019, 8, 383.	2.4	20
101	Glucose Variables in Type 1 Diabetes Studies With Dapagliflozin: Pooled Analysis of Continuous Glucose Monitoring Data From DEPICT-1 and -2. Diabetes Care, 2019, 42, 1081-1087.	8.6	40
102	Glycaemic control on nutritional support: finding stability in unstable times. Lancet Diabetes and Endocrinology,the, 2019, 7, 330-331.	11.4	0
103	Cytokine-induced translocation of GRP78 to the plasma membrane triggers a pro-apoptotic feedback loop in pancreatic beta cells. Cell Death and Disease, 2019, 10, 309.	6.3	53
104	International Consensus on Risk Management of Diabetic Ketoacidosis in Patients With Type 1 Diabetes Treated With Sodium–Glucose Cotransporter (SGLT) Inhibitors. Diabetes Care, 2019, 42, 1147-1154.	8.6	249
105	Data on inflammatory cytokines and pathways involved in clearance of Nontypeable Haemophilus influenzae from the lungs during cigarette smoking and vitamin D deficiency. Data in Brief, 2019, 22, 703-708.	1.0	3
106	Occurrence of Diabetic Nephropathy After Renal Transplantation Despite Intensive Glycemic Control: An Observational Cohort Study. Diabetes Care, 2019, 42, 625-634.	8.6	19
107	Other Forms of Immunosuppression. , 2019, , 313-332.		0
108	Investigating the Association Between Baseline Characteristics (HbA1c and Body Mass Index) and Clinical Outcomes of Fast-Acting Insulin Aspart in People with Diabetes: A Post Hoc Analysis. Diabetes Therapy, 2019, 10, 177-188.	2.5	2

#	Article	IF	CITATIONS
109	Vitamin D-modulated dendritic cells delay lethal graft-versus-host disease through induction of regulatory T cells. Journal of Steroid Biochemistry and Molecular Biology, 2019, 188, 103-110.	2.5	26
110	Clinical Pharmacology of Fast-Acting Insulin Aspart Versus Insulin Aspart Measured as Free or Total Insulin Aspart and the Relation to Anti-Insulin Aspart Antibody Levels in Subjects with Type 1 Diabetes Mellitus. Clinical Pharmacokinetics, 2019, 58, 639-649.	3.5	8
111	Vitamin D controls the capacity of human dendritic cells to induce functional regulatory T cells by regulation of glucose metabolism. Journal of Steroid Biochemistry and Molecular Biology, 2019, 187, 134-145.	2.5	71
112	Airway infection with Nontypeable Haemophilus influenzae is more rapidly eradicated in vitamin D deficient mice. Journal of Steroid Biochemistry and Molecular Biology, 2019, 187, 42-51.	2.5	13
113	Natural killer cells induce neutrophil extracellular trap formation in venous thrombosis. Journal of Thrombosis and Haemostasis, 2019, 17, 403-414.	3.8	38
114	Hysterectomy by transvaginal natural orifice transluminal endoscopic surgery versus laparoscopy as a dayâ€care procedure: aArandomised controlled trial. BJOG: an International Journal of Obstetrics and Gynaecology, 2019, 126, 105-113.	2.3	112
115	Sustained 52â€week efficacy and safety of triple therapy with dapagliflozin plus saxagliptin versus dual therapy with sitagliptin added to metformin in patients with uncontrolled type 2 diabetes. Diabetes, Obesity and Metabolism, 2019, 21, 883-892.	4.4	16
116	Artificial Pancreas Systems for People With Type 2 Diabetes: Conception and Design of the European CLOSE Project. Journal of Diabetes Science and Technology, 2019, 13, 261-267.	2.2	13
117	Screening for hypovitaminosis D: cost-effective or not?. European Journal of Endocrinology, 2019, 180, D1-D7.	3.7	9
118	Risk factor screening for gestational diabetes mellitus based on the 2013 WHO criteria. European Journal of Endocrinology, 2019, 180, 353-363.	3.7	39
119	1231-P: Dapagliflozin (DAPA) in Type 1 Diabetes (T1D): Pooled Outcomes from DEPICT-1 and -2. Diabetes, 2019, 68, .	0.6	3
120	Einsichten aus der Analyse von 24h Fastenperioden als Basalraten-Test bei Insulinpumpen-behandelten Patietnen mit Typ 1-Diabetes. , 2019, 14, .		0
121	Langzeit-Wirksamkeit und -VertrÄ g lichkeit von Dapagliflozin bei Patienten mit unzureichend kontrolliertem Typ 1 Diabetes: die DEPICT-1-Studie. Diabetologie Und Stoffwechsel, 2019, 14, .	0.0	0
122	2136-P: Effects of Cytokine Exposure on the Proteome of Human Islets as Evaluated by Shotgun and 2DE Analysis. Diabetes, 2019, 68, 2136-P.	0.6	0
123	1199-P: Analysis of Patient Preferences for Adjunct Therapy to Insulin in T1D. Diabetes, 2019, 68, 1199-P.	0.6	0
124	1105-P: Impact of Switching from Twice-Daily Basal Insulin (BI) to Once-Daily Insulin Glargine 300 U/mL (Gla-300) in Patients with Type 1 Diabetes (T1DM): Phase 4 Optimize Study. Diabetes, 2019, 68, .	0.6	1
125	Stem-cell-based Therapies for Improving Islet Transplantation Outcomes in Type 1 Diabetes. Current Diabetes Reviews, 2018, 14, 3-13.	1.3	11
126	Effect of Continuous Glucose Monitoring on Glycemic Control, Acute Admissions, and Quality of Life: A Real-World Study. Journal of Clinical Endocrinology and Metabolism, 2018, 103, 1224-1232.	3.6	125

#	Article	IF	CITATIONS
127	Effect of once weekly dulaglutide by baseline betaâ€cell function in people with type 2 diabetes in the AWARD programme. Diabetes, Obesity and Metabolism, 2018, 20, 2023-2028.	4.4	20
128	Safety and tolerability of dapagliflozin, saxagliptin and metformin in combination: <i><scp>P</scp>ostâ€hoc</i> analysis of concomitant addâ€on versus sequential addâ€on to metformin and of triple versus dual therapy with metformin. Diabetes, Obesity and Metabolism, 2018, 20, 1542-1546.	4.4	17
129	Accuracy and precision of flash glucose monitoring sensors inserted into the abdomen and upper thigh compared with the upper arm. Diabetes, Obesity and Metabolism, 2018, 20, 1503-1507.	4.4	25
130	Transvaginal natural orifice transluminal endoscopic surgery (vNOTES) adnexectomy for benign pathology compared with laparoscopic excision (NOTABLE): a protocol for a randomised controlled trial. BMJ Open, 2018, 8, e018059.	1.9	37
131	Inhibition of histone deacetylase 6 (HDAC6) protects against vincristine-induced peripheral neuropathies and inhibits tumor growth. Neurobiology of Disease, 2018, 111, 59-69.	4.4	52
132	Efficacy and safety of fastâ€acting insulin aspart in comparison with insulin aspart in type 1 diabetes (onset 1): A 52â€week, randomized, treatâ€ŧoâ€ŧarget, phase III trial. Diabetes, Obesity and Metabolism, 2018, 20, 1148-1155.	4.4	68
133	Efficacy of dapagliflozin as an adjunct therapy in patients with inadequately controlled type 1 diabetes mellitus. Expert Opinion on Pharmacotherapy, 2018, 19, 617-622.	1.8	2
134	Are We There Yet? Finding Ways to Work Together on T1D. Diabetes Care, 2018, 41, 667-669.	8.6	3
135	Metformin extendedâ€release versus immediateâ€release: <scp>A</scp> n international, randomized, doubleâ€blind, headâ€toâ€head trial in pharmacotherapyâ€naĂ⁻ve patients with type 2 diabetes. Diabetes, Obesi and Metabolism, 2018, 20, 463-467.	ty4.4	25
136	BNIP3 modulates the interface between B16-F10 melanoma cells and immune cells. Oncotarget, 2018, 9, 17631-17644.	1.8	12
137	Cover Image, Volume 20, Issue 6. Diabetes, Obesity and Metabolism, 2018, 20, i-i.	4.4	0
138	Dapagliflozin versus saxagliptin as add-on therapy in patients with type 2 diabetes inadequately controlled with metformin. Archives of Endocrinology and Metabolism, 2018, 62, 424-430.	0.6	11
139	Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. Lancet, The, 2018, 392, 1519-1529.	13.7	1,179
140	Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia, 2018, 61, 2461-2498.	6.3	1,002
141	Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care, 2018, 41, 2669-2701.	8.6	2,190
142	Inflammation-Induced Citrullinated Glucose-Regulated Protein 78 Elicits Immune Responses in Human Type 1 Diabetes. Diabetes, 2018, 67, 2337-2348.	0.6	56
143	Efficacy and Safety of Dapagliflozin in Patients With Inadequately Controlled Type 1 Diabetes: The DEPICT-1 52-Week Study. Diabetes Care, 2018, 41, 2552-2559.	8.6	177
144	Screening and Management of Gestational Diabetes Mellitus after Bariatric Surgery. Nutrients, 2018, 10, 1479.	4.1	32

#	Article	IF	CITATIONS
145	A Modified Two-Step Screening Strategy for Gestational Diabetes Mellitus Based on the 2013 WHO Criteria by Combining the Glucose Challenge Test and Clinical Risk Factors. Journal of Clinical Medicine, 2018, 7, 351.	2.4	33
146	Immunological biomarkers for the development and progression of type 1 diabetes. Diabetologia, 2018, 61, 2252-2258.	6.3	51
147	Vhl deletion in osteoblasts boosts cellular glycolysis and improves global glucose metabolism. Journal of Clinical Investigation, 2018, 128, 1087-1105.	8.2	75
148	Characterization of the Open-Label Lead-In Period of Two Randomized Controlled Phase 3 Trials Evaluating Dapagliflozin, Saxagliptin, and Metformin in Type 2 Diabetes. Diabetes Therapy, 2018, 9, 1703-1711.	2.5	3
149	The need for appropriate registration of pregnancy outcomes under newer oral glucoseâ€lowering therapies. Diabetes, Obesity and Metabolism, 2018, 20, 2477-2480.	4.4	1
150	Magnetoliposomes as Contrast Agents for Longitudinal in vivo Assessment of Transplanted Pancreatic Islets in a Diabetic Rat Model. Scientific Reports, 2018, 8, 11487.	3.3	10
151	At similar weight loss, dietary composition determines the degree of glycemic improvement in diet-induced obese C57BL/6 mice. PLoS ONE, 2018, 13, e0200779.	2.5	6
152	Vitamin D and Diabetes. , 2018, , 969-987.		1
153	Efficacy and Safety of Dapagliflozin in Patients With Inadequately Controlled Type 1 Diabetes (the) Tj ETQq1 1 0	.784314 r	gBT_/Overlock
154	The Sensitivity and Specificity of the Glucose Challenge Test in a Universal Two-Step Screening Strategy for Gestational Diabetes Mellitus Using the 2013 World Health Organization Criteria. Diabetes Care, 2018, 41, e111-e112.	8.6	65
155	Long-Term Efficacy and Safety of Dapagliflozin in Patients with Inadequately Controlled Type 1 Diabetes—The DEPICT-1 Study. Diabetes, 2018, 67, 119-LB.	0.6	9
156	Glucose Variables in T1D Studies with Dapagliflozin—Pooled Analysis of Continuous Glucose Monitoring Data from DEPICT-1 and 2. Diabetes, 2018, 67, 125-LB.	0.6	2
157	Efficacy and Safety of Dapagliflozin in Patients with Inadequately Controlled Type 1 Diabetes—DEPICT-2 Study. Diabetes, 2018, 67, 213-OR.	0.6	11
158	Developments in the Management of Type 1 and Type 2 Diabetes. European Endocrinology, 2018, 14, 13.	1.5	1
159	Empagliflozin reduces mortality in analyses adjusted for control of blood pressure, low density lipoprotein cholesterol and HbA1c over time. Diabetologie Und Stoffwechsel, 2018, 13, .	0.0	0
160	High fat diet induces a tumor like metabolism in the liver. Journal of Hepatology, 2018, 68, S661.	3.7	0
161	Impact of Switching from Twice-Daily Basal Insulin to Once-Daily Insulin Glargine 300 U/mL (Gla-300) in Patients with Type 1 Diabetes (T1DM)—Phase 4 OPTIMIZE Study, Belgian Cohort. Diabetes, 2018, 67, .	0.6	0
162	Modulation of Dapagliflozin-Associated Genital Tract Infections by Saxagliptin—A Pooled Safety Analysis. Diabetes, 2018, 67, .	0.6	0

#	Article	IF	CITATIONS
163	Does vitamin D play a role in autoimmune endocrine disorders? A proof of concept. Reviews in Endocrine and Metabolic Disorders, 2017, 18, 335-346.	5.7	134
164	Early differences in islets from prediabetic NOD mice: combined microarray and proteomic analysis. Diabetologia, 2017, 60, 475-489.	6.3	31
165	Prospects of a type 1 diabetes vaccine. Expert Opinion on Biological Therapy, 2017, 17, 403-406.	3.1	8
166	1β,25-Dihydroxyvitamin D 3 : A new vitamin D metabolite in human serum. Journal of Steroid Biochemistry and Molecular Biology, 2017, 173, 341-348.	2.5	18
167	Insulin analogues in type 1 diabetes mellitus: getting better all the time. Nature Reviews Endocrinology, 2017, 13, 385-399.	9.6	170
168	Impact on Experimental Colitis of Vitamin D Receptor Deletion in Intestinal Epithelial or Myeloid Cells. Endocrinology, 2017, 158, 2354-2366.	2.8	26
169	Vitamin D endocrinology on the cross-road between immunity and metabolism. Molecular and Cellular Endocrinology, 2017, 453, 52-67.	3.2	82
170	Role of Continuous Glucose Monitoring in Clinical Trials: Recommendations on Reporting. Diabetes Technology and Therapeutics, 2017, 19, 391-399.	4.4	45
171	Factors Associated With Diabetes-Specific Health-Related Quality of Life in Youth With Type 1 Diabetes: The Global TEENs Study. Diabetes Care, 2017, 40, 1002-1009.	8.6	122
172	Introduction of biosimilar insulins in Europe. Diabetic Medicine, 2017, 34, 1340-1353.	2.3	36
173	Steviol glycosides enhance pancreatic beta-cell function and taste sensation by potentiation of TRPM5 channel activity. Nature Communications, 2017, 8, 14733.	12.8	136
174	Fast-Acting Insulin Aspart Improves Glycemic Control in Basal-Bolus Treatment for Type 1 Diabetes: Results of a 26-Week Multicenter, Active-Controlled, Treat-to-Target, Randomized, Parallel-Group Trial (onset 1). Diabetes Care, 2017, 40, 943-950.	8.6	148
175	Promise of SCLT2 Inhibitors in Heart Failure: Diabetes and Beyond. Current Treatment Options in Cardiovascular Medicine, 2017, 19, 23.	0.9	69
176	Metformin as addâ€on to intensive insulin therapy in type 1 diabetes mellitus. Diabetes, Obesity and Metabolism, 2017, 19, 1463-1467.	4.4	21
177	Differentiation of Diabetes by Pathophysiology, Natural History, and Prognosis. Diabetes, 2017, 66, 241-255.	0.6	454
178	Regulation of Immune Function by Vitamin D and Its Use in Diseases of Immunity. Endocrinology and Metabolism Clinics of North America, 2017, 46, 1061-1094.	3.2	143
179	Differential transcriptome of tolerogenic versus inflammatory dendritic cells points to modulated T1D genetic risk and enriched immune regulation. Genes and Immunity, 2017, 18, 176-183.	4.1	32
180	Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-blind, phase 3, randomised controlled trial. Lancet Diabetes and Endocrinology,the, 2017, 5, 864-876.	11.4	244

#	Article	IF	CITATIONS
181	Benefits of flu vaccination for persons with diabetes mellitus: A review. Vaccine, 2017, 35, 5095-5101.	3.8	84
182	Age and Early Graft Function Relate With Risk-Benefit Ratio of Allogenic Islet Transplantation Under Antithymocyte Globulin-Mycophenolate Mofetil-Tacrolimus Immune Suppression. Transplantation, 2017, 101, 2218-2227.	1.0	3
183	Twenty-Year Progression Rate to Clinical Onset According to Autoantibody Profile, Age, and <i>HLA-DQ</i> Genotype in a Registry-Based Group of Children and Adults With a First-Degree Relative With Type 1 Diabetes. Diabetes Care, 2017, 40, 1065-1072.	8.6	43
184	Relationship Between Duration of Type 2 Diabetes and Effectiveness of DPP-4 Inhibitor Versus Sulfonylurea as Add-on Therapy: A Post Hoc Analysis. Diabetes Therapy, 2017, 8, 829-836.	2.5	4
185	Factors associated with Prolonged Inaction in the hypoglycaemic treatment in people with non-insulin dependent Type 2 Diabetes and elevated glycated haemoglobin: A registry-based cohort study. Primary Care Diabetes, 2017, 11, 482-489.	1.8	4
186	Understanding type 1 diabetes through proteomics. Expert Review of Proteomics, 2017, 14, 571-580.	3.0	8
187	Characteristics and cardiovascular complications of a large cohort of adults diagnosed with type 2 diabetesÂ<45Âyears. Diabetology and Metabolic Syndrome, 2017, 9, 28.	2.7	6
188	Rebranding asymptomatic type 1 diabetes: the case for autoimmune beta cell disorder as a pathological and diagnostic entity. Diabetologia, 2017, 60, 35-38.	6.3	28
189	Reversal of Diabetes in NOD Mice by Clinical-Grade Proinsulin and IL-10–Secreting Lactococcus lactis in Combination With Low-Dose Anti-CD3 Depends on the Induction of Foxp3-Positive T Cells. Diabetes, 2017, 66, 448-459.	0.6	57
190	Impact of the mode of protraction of basal insulin therapies on their pharmacokinetic and pharmacodynamic properties and resulting clinical outcomes. Diabetes, Obesity and Metabolism, 2017, 19, 3-12.	4.4	84
191	Human multipotent adult progenitor cells enhance islet function and revascularisation when co-transplanted as a composite pellet in a mouse model of diabetes. Diabetologia, 2017, 60, 134-142.	6.3	21
192	Postoperative outcomes and quality of life following hysterectomy by natural orifice transluminal endoscopic surgery (NOTES) compared to laparoscopy in women with a non-prolapsed uterus and benign gynaecological disease: a systematic review and meta-analysis. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2017, 208, 6-15.	1.1	43
193	Efficacy and Safety of Fast-acting Insulin Aspart Are Maintained over 52 weeks: Comparison with Insulin Aspart in Onset 1. Canadian Journal of Diabetes, 2017, 41, S56-S57.	0.8	1
194	Quantitative Polymerase Chain Reaction. , 2017, , 41-58.		2
195	Implementing a Reminder System in the Northern Part of Belgium to Stimulate Postpartum Screening for Glucose Intolerance in Women with Gestational Diabetes: The "Sweet Pregnancy―Project. International Journal of Endocrinology, 2017, 2017, 1-9.	1.5	22
196	MIF inhibition interferes with the inflammatory and T cell-stimulatory capacity of NOD macrophages and delays autoimmune diabetes onset. PLoS ONE, 2017, 12, e0187455.	2.5	12
197	Clinical Safety and Tolerability of Vildagliptin – Insights from Randomised Trials, Observational Studies and Post-marketing Surveillance. European Endocrinology, 2017, 13, 68.	1.5	23
198	Lactococcus lactis As a Versatile Vehicle for Tolerogenic Immunotherapy. Frontiers in Immunology, 2017, 8, 1961.	4.8	37

#	Article	IF	CITATIONS
199	Clinical action measures improve the reliability of feedback on quality of care in diabetes centres: a retrospective cohort study. BMC Health Services Research, 2016, 16, 424.	2.2	2
200	Glucose Intolerance after a Recent History of Gestational Diabetes Based on the 2013 WHO Criteria. PLoS ONE, 2016, 11, e0157272.	2.5	33
201	1,25-Dihydroxyvitamin D Modulates Antibacterial and Inflammatory Response in Human Cigarette Smoke-Exposed Macrophages. PLoS ONE, 2016, 11, e0160482.	2.5	37
202	HALON—hysterectomy by transabdominal laparoscopy or natural orifice transluminal endoscopic surgery: a randomised controlled trial (study protocol). BMJ Open, 2016, 6, e011546.	1.9	20
203	Ubiquitin D Regulates IRE1α/c-Jun N-terminal Kinase (JNK) Protein-dependent Apoptosis in Pancreatic Beta Cells. Journal of Biological Chemistry, 2016, 291, 12040-12056.	3.4	44
204	Screening for gestational diabetes in Europe: where do we stand and how to move forward?. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2016, 201, 192-196.	1.1	21
205	Maternal obesity in Europe: where do we stand and how to move forward?. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2016, 201, 203-208.	1.1	140
206	Long-term effects of gastric bypass surgery on psychosocial well-being and eating behavior: not all that glitters is gold. Acta Clinica Belgica, 2016, 71, 395-402.	1.2	7
207	Survey by the European Board and College of Obstetrics and Gynaecology on screening for gestational diabetes in Europe. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2016, 201, 197-202.	1.1	53
208	Effectiveness of vildagliptin versus other oral antidiabetes drugs as add-on to sulphonylurea monotherapy: Post hoc analysis from the EDGE study. Primary Care Diabetes, 2016, 10, 452-458.	1.8	0
209	Risk factors for large-for-gestational age infants in pregnant women with type 1 diabetes. BMC Pregnancy and Childbirth, 2016, 16, 162.	2.4	34
210	Insulin degludec + liraglutide: a complementary combination. Expert Opinion on Biological Therapy, 2016, 16, 1171-1177.	3.1	1
211	Efficacy and Safety of Liraglutide Added to Capped Insulin Treatment in Subjects With Type 1 Diabetes: The ADJUNCT TWO Randomized Trial. Diabetes Care, 2016, 39, 1693-1701.	8.6	159
212	Efficacy and Safety of Liraglutide Added to Insulin Treatment in Type 1 Diabetes: The ADJUNCT ONE Treat-To-Target Randomized Trial. Diabetes Care, 2016, 39, 1702-1710.	8.6	200
213	Efficacy and safety of canagliflozin when used in conjunction with incretinâ€mimetic therapy in patients with type 2 diabetes. Diabetes, Obesity and Metabolism, 2016, 18, 82-91.	4.4	74
214	Efficacy and safety of triple therapy with dapagliflozin addâ€on to saxagliptin plus metformin over 52 weeks in patients with type 2 diabetes. Diabetes, Obesity and Metabolism, 2016, 18, 1134-1137.	4.4	52
215	Analysis of self-antigen specificity of islet-infiltrating T cells from human donors with type 1 diabetes. Nature Medicine, 2016, 22, 1482-1487.	30.7	232
216	A metaâ€analysis of rate ratios for nocturnal confirmed hypoglycaemia with insulin degludec vs. insulin glargine using different definitions for hypoglycaemia. Diabetic Medicine, 2016, 33, 478-487.	2.3	35

#	Article	IF	CITATIONS
217	The phenotype and function of murine bone marrow-derived dendritic cells is not affected by the absence of VDR or its ability to bind 1α,25-dihydroxyvitamin D3. Journal of Steroid Biochemistry and Molecular Biology, 2016, 164, 239-245.	2.5	4
218	Effect of a transcriptional inactive or absent vitamin D receptor on beta-cell function and glucose homeostasis in mice. Journal of Steroid Biochemistry and Molecular Biology, 2016, 164, 309-317.	2.5	13
219	Vitamin D deficiency impairs skeletal muscle function in a smoking mouse model. Journal of Endocrinology, 2016, 229, 97-108.	2.6	13
220	Mortality in Individuals Treated With Glucose-Lowering Agents: A Large, Controlled Cohort Study. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 461-469.	3.6	23
221	The microRNA-29 Family Dictates the Balance Between Homeostatic and Pathological Glucose Handling in Diabetes and Obesity. Diabetes, 2016, 65, 53-61.	0.6	114
222	Performance of strip-based glucose meters and cassette-based blood gas analyzer for monitoring glucose levels in a surgical intensive care setting. Clinical Chemistry and Laboratory Medicine, 2016, 54, 169-80.	2.3	8
223	Glibenclamide Prevents Diabetes in NOD Mice. PLoS ONE, 2016, 11, e0168839.	2.5	19
224	Sodium-glucose Cotransporter 2 Inhibitors and Ketoacidosis – Clinical Implications in the Treatment of Patients with Type 2 Diabetes. European Endocrinology, 2016, 12, 33.	1.5	0
225	Trimming of two major type 1 diabetes driving antigens, GAD65 and IA-2, allows for successful expression in Lactococcus lactis. Beneficial Microbes, 2015, 6, 591-601.	2.4	11
226	Differences in pregnancy outcomes and characteristics between insulin- and diet-treated women with gestational diabetes. BMC Pregnancy and Childbirth, 2015, 15, 271.	2.4	45
227	Vitamin D deficiency exacerbates COPD-like characteristics in the lungs of cigarette smoke-exposed mice. Respiratory Research, 2015, 16, 110.	3.6	42
228	Clinical Immunosuppressants Inhibit Inflammatory, Proliferative, and Reprogramming Potential, But not Angiogenesis of Human Pancreatic Duct Cells. Cell Transplantation, 2015, 24, 1585-1598.	2.5	1
229	Leptin-adiponectin ratio in pre-diabetic patients undergoing percutaneous coronary intervention. Acta Cardiologica, 2015, 70, 640-646.	0.9	10
230	Association of Adipose Tissue Inflammation With Histologic Severity of Nonalcoholic Fatty Liver Disease. Gastroenterology, 2015, 149, 635-648.e14.	1.3	249
231	A proposal for the use of uniform diagnostic criteria for gestational diabetes in Europe: an opinion paper by the European Board & College of Obstetrics and Gynaecology (EBCOG). Diabetologia, 2015, 58, 1422-1429.	6.3	55
232	Glucose intolerance in early postpartum in women with gestational diabetes: Who is at increased risk?. Primary Care Diabetes, 2015, 9, 244-252.	1.8	24
233	Vitamin D3 Induces Tolerance in Human Dendritic Cells by Activation of Intracellular Metabolic Pathways. Cell Reports, 2015, 10, 711-725.	6.4	228
234	The betaâ€cell in type 1 diabetes: What have we learned from proteomic studies?. Proteomics - Clinical Applications, 2015, 9, 755-766.	1.6	19

#	Article	IF	CITATIONS
235	BMI is an important driver of β-cell loss in type 1 diabetes upon diagnosis in 10 to 18-year-old children. European Journal of Endocrinology, 2015, 172, 107-113.	3.7	42
236	Care trajectories are associated with quality improvement in the treatment of patients with uncontrolled type 2 diabetes: A registry based cohort study. Primary Care Diabetes, 2015, 9, 354-361.	1.8	7
237	A proteomic study of the regulatory role for STATâ€1 in cytokineâ€induced betaâ€cell death. Proteomics - Clinical Applications, 2015, 9, 938-952.	1.6	4
238	Vitamin D and diabetes: Where do we stand?. Diabetes Research and Clinical Practice, 2015, 108, 201-209.	2.8	88
239	SGLT-2 Inhibitors: Potential Novel Strategy to Prevent Congestive Heart Failure in Diabetes?. Current Cardiovascular Risk Reports, 2015, 9, 1.	2.0	7
240	Low cytochrome oxidase 411 links mitochondrial dysfunction to obesity and type 2 diabetes in humans and mice. International Journal of Obesity, 2015, 39, 1254-1263.	3.4	24
241	Cereulide food toxin, beta cell function and diabetes: Facts and hypotheses. Diabetes Research and Clinical Practice, 2015, 109, 1-5.	2.8	13
242	Prognostic value of metabolic parameters and clinical impact of 18F-fluorocholine PET/CT in biochemical recurrent prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2015, 42, 1784-1793.	6.4	32
243	A Randomized Clinical Trial to Evaluate the Efficacy and Safety of Co-Administration of Sitagliptin with Intensively Titrated Insulin Glargine. Diabetes Therapy, 2015, 6, 127-142.	2.5	37
244	Antitumor Immunity Triggered by Melphalan Is Potentiated by Melanoma Cell Surface–Associated Calreticulin. Cancer Research, 2015, 75, 1603-1614.	0.9	86
245	Achievement of treatment goals with canagliflozin in patients with type 2 diabetes mellitus: a pooled analysis of randomized controlled trials. Current Medical Research and Opinion, 2015, 31, 1993-2000.	1.9	10
246	Metformin-associated lactic acidosis: time to let it go?. Journal of Diabetes and Its Complications, 2015, 29, 974-975.	2.3	9
247	Clinical Utility of SMBG: Recommendations on the Use and Reporting of SMBG in Clinical Research. Diabetes Care, 2015, 38, 1627-1633.	8.6	28
248	Randomized, Double-Blind, Phase 3 Trial of Triple Therapy With Dapagliflozin Add-on to Saxagliptin Plus Metformin in Type 2 Diabetes. Diabetes Care, 2015, 38, 2009-2017.	8.6	106
249	A Decision Support Tool for Appropriate Glucose-Lowering Therapy in Patients with Type 2 Diabetes. Diabetes Technology and Therapeutics, 2015, 17, 194-202.	4.4	15
250	Citrullinated Glucose-Regulated Protein 78 Is an Autoantigen in Type 1 Diabetes. Diabetes, 2015, 64, 573-586.	0.6	136
251	Modulation of insulin dose titration using a hypoglycaemiaâ€sensitive algorithm: insulin glargine versus neutral protamine Hagedorn insulin in insulinâ€naÃ⁻ve people with type 2 diabetes. Diabetes, Obesity and Metabolism, 2015, 17, 15-22.	4.4	21

252 Domestication and Responses to Stress. , 2015, , 743-760.

#	Article	IF	CITATIONS
253	LATE-BREAKING ABSTRACT: Effect of vitamin D on inflammatory and antibacterial responses to cigarette smoke. , 2015, , .		0
254	Antigen-Specific Therapy With Human Proinsulin and IL10 in Combination With Short-Course Monoclonal CD3 Antibody in Preclinical Models of Islet Transplant Transplantation, 2014, 98, 356-357.	1.0	0
255	A Combined "Omics―Approach Identifies N-Myc Interactor as a Novel Cytokine-induced Regulator of IRE1α Protein and c-Jun N-terminal Kinase in Pancreatic Beta Cells. Journal of Biological Chemistry, 2014, 289, 20677-20693.	3.4	34
256	PDLIM2 expression is driven by vitamin D and is involved in the pro-adhesion, and anti-migration and -invasion activity of vitamin D. Oncogene, 2014, 33, 1904-1911.	5.9	42
257	Bariatric Surgery Induces Weight Loss but Does Not Improve Glycemic Control in Patients With Type 1 Diabetes. Diabetes Care, 2014, 37, e173-e174.	8.6	34
258	Glucose Intolerance after a Recent History of Gestational Diabetes. International Journal of Endocrinology, 2014, 2014, 1-9.	1.5	13
259	OP60 EFFICACY AND SAFETY OF LIRAGLUTIDE VERSUS PLACEBO IN SUBJECTS WITH TYPE 2 DIABETES AND MODERATE RENAL IMPAIRMENT (LIRA-RENAL): A RANDOMISED TRIAL. Diabetes Research and Clinical Practice, 2014, 106, S31.	2.8	1
260	PO121 RATE RATIOS FOR NOCTURNAL CONFIRMED HYPOGLYCAEMIA WITH INSULIN DEGLUDEC VS. INSULIN GLARGINE USING DIFFERENT DEFINITIONS. Diabetes Research and Clinical Practice, 2014, 106, S109.	2.8	0
261	Health status and hypoglycaemia with insulin degludec versus insulin glargine: a 2â€year trial in insulinâ€naÃ⁻ve patients with type 2 diabetes. Diabetes, Obesity and Metabolism, 2014, 16, 869-872.	4.4	7
262	Dietary Supplementation With High Doses of Regular Vitamin D3 Safely Reduces Diabetes Incidence in NOD Mice When Given Early and Long Term. Diabetes, 2014, 63, 2026-2036.	0.6	66
263	Vitamin D for infections. Current Opinion in Endocrinology, Diabetes and Obesity, 2014, 21, 431-436.	2.3	41
264	Patient-reported frequency, awareness and patient-physician communication of hypoglycaemia in Belgium. Acta Clinica Belgica, 2014, 69, 439-445.	1.2	17
265	MECHANISMS IN ENDOCRINOLOGY: Vitamin D as a potential contributor in endocrine health and disease. European Journal of Endocrinology, 2014, 171, R101-R110.	3.7	122
266	Effectiveness and tolerability of second-line therapy with vildagliptin versus other oral agents in type 2 diabetes (EDGE):post-hocsubanalysis of the Belgian data. Acta Clinica Belgica, 2014, 69, 171-176.	1.2	3
267	Early Alteration of Kidney Function in Nonuremic Type 1 Diabetic Islet Transplant Recipients Under Tacrolimus-Mycophenolate Therapy. Transplantation, 2014, 98, 451-457.	1.0	12
268	Administering 25-hydroxyvitamin D3 in vitamin D-deficient young type 1A diabetic patients reduces reactivity against islet autoantigens. Clinical Nutrition, 2014, 33, 1153-1156.	5.0	18
269	lslet infiltration, cytokine expression and beta cell death in the NOD mouse, BB rat, Komeda rat, LEW.1AR1-iddm rat and humans with type 1 diabetes. Diabetologia, 2014, 57, 512-521.	6.3	76
270	Influence of domestication process on immune response to repeated emersion stressors in Eurasian perch (Perca fluviatilis, L.). Comparative Biochemistry and Physiology Part A, Molecular & Integrative Physiology, 2014, 173, 52-60.	1.8	16

#	Article	IF	CITATIONS
271	1,25-Dihydroxyvitamin D3 Promotes Tolerogenic Dendritic Cells with Functional Migratory Properties in NOD Mice. Journal of Immunology, 2014, 192, 4210-4220.	0.8	112
272	A comparison of adding liraglutide versus a single daily dose of insulin aspart to insulin degludec in subjects with type 2 diabetes (<scp>BEGIN</scp> : <scp>VICTOZA ADDâ€ON</scp>). Diabetes, Obesity and Metabolism, 2014, 16, 636-644.	4.4	150
273	Efficacy of vildagliptin versus sulfonylureas as add-on therapy to metformin: comparison of results from randomised controlled and observational studies. Diabetologia, 2014, 57, 1304-1307.	6.3	39
274	IL-17A increases the expression of proinflammatory chemokines in human pancreatic islets. Diabetologia, 2014, 57, 502-511.	6.3	47
275	Ageâ€dependent decline of βâ€cell function in type 1 diabetes after diagnosis: a multiâ€centre longitudinal study. Diabetes, Obesity and Metabolism, 2014, 16, 262-267.	4.4	79
276	Achievement of Diabetes-Related Treatment Goals with Canagliflozin (CANA) in Patients with Type 2 Diabetes Mellitus (T2DM). Canadian Journal of Diabetes, 2014, 38, S58-S59.	0.8	0
277	Fetal Macrosomia and Neonatal Hyperinsulinemic Hypoglycemia Associated With Transplacental Transfer of Sulfonylurea in a Mother With <i>KCNJ11</i> Related Neonatal Diabetes. Diabetes Care, 2014, 37, 3333-3335.	8.6	19
278	Oral Delivery of Glutamic Acid Decarboxylase (GAD)-65 and IL10 by <i>Lactococcus lactis</i> Reverses Diabetes in Recent-Onset NOD Mice. Diabetes, 2014, 63, 2876-2887.	0.6	129
279	The proapoptotic BH3-only proteins Bim and Puma are downstream of endoplasmic reticulum and mitochondrial oxidative stress in pancreatic islets in response to glucotoxicity. Cell Death and Disease, 2014, 5, e1124-e1124.	6.3	93
280	The Belgian Diabetes in Pregnancy Study (BEDIP-N), a multi-centric prospective cohort study on screening for diabetes in pregnancy and gestational diabetes: methodology and design. BMC Pregnancy and Childbirth, 2014, 14, 226.	2.4	30
281	Foodborne cereulide causes beta cell dysfunction and apoptosis. Archives of Public Health, 2014, 72, .	2.4	1
282	Discovery of Molecular Pathways Mediating 1,25-Dihydroxyvitamin D3 Protection Against Cytokine-Induced Inflammation and Damage of Human and Male Mouse Islets of Langerhans. Endocrinology, 2014, 155, 736-747.	2.8	45
283	A proteomic approach on the effects of TX527, a 1α,25-dihydroxyvitamin D3 analog, in human T lymphocytes. Journal of Steroid Biochemistry and Molecular Biology, 2014, 144, 96-101.	2.5	1
284	Lysine deacetylase inhibition prevents diabetes by chromatin-independent immunoregulation and β-cell protection. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 1055-1059.	7.1	58
285	Foodborne Cereulide Causes Beta-Cell Dysfunction and Apoptosis. PLoS ONE, 2014, 9, e104866.	2.5	36
286	Combining MK626, a Novel DPP-4 Inhibitor, and Low-Dose Monoclonal CD3 Antibody for Stable Remission of New-Onset Diabetes in Mice. PLoS ONE, 2014, 9, e107935.	2.5	17
287	1,25-Dihydroxyvitamin D3 and Its Analog TX527 Promote a Stable Regulatory T Cell Phenotype in T Cells from Type 1 Diabetes Patients. PLoS ONE, 2014, 9, e109194.	2.5	56

288 Other Forms of Immunosuppression. , 2014, , 320-338.

#	Article	IF	CITATIONS
289	The Story of NAIMIT – A Framework 7 Project on Type 1 Diabetes. European Endocrinology, 2014, 10, 100.	1.5	0
290	No evidence for a role of rare <i>CYP27B1</i> functional variations in multiple sclerosis. Annals of Neurology, 2013, 73, 433-437.	5.3	31
291	Optimal Vitamin D Status: A Critical Analysis on the Basis of Evidence-Based Medicine. Journal of Clinical Endocrinology and Metabolism, 2013, 98, E1283-E1304.	3.6	234
292	Vitamin D and diabetes: the odd couple. Trends in Endocrinology and Metabolism, 2013, 24, 561-568.	7.1	56
293	The vitamin D analog TX527 ameliorates disease symptoms in a chemically induced model of inflammatory bowel disease. Journal of Steroid Biochemistry and Molecular Biology, 2013, 136, 107-111.	2.5	29
294	Effects Of Patient-Reported Hypoglycaemia On Resource Use And Patient Well-Being In Belgium. Value in Health, 2013, 16, A166.	0.3	0
295	Immune response of gravid Eurasian perch to isolation and confinement rearing conditions. Fish and Shellfish Immunology, 2013, 34, 1723.	3.6	0
296	Canagliflozin (CANA) Added on to Dipeptidyl Peptidase-4 Inhibitors (DPP-4i) or Glucagon-like Peptide-1 (GLP-1) Agonists with or Without Other Antihyperglycemic Agents (AHAs) in Type 2 Diabetes Mellitus (T2DM). Canadian Journal of Diabetes, 2013, 37, S38.	0.8	1
297	Vitamin D in thyroid tumorigenesis and development. Progress in Histochemistry and Cytochemistry, 2013, 48, 65-98.	5.1	42
298	Using Exenatide Twice Daily or Insulin in Clinical Practice: Results from CHOICE. Diabetes Therapy, 2013, 4, 285-308.	2.5	12
299	Screening for pregestational and gestational diabetes in pregnancy: a survey of obstetrical centers in the northern part of Belgium. Diabetology and Metabolic Syndrome, 2013, 5, 66.	2.7	14
300	Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trial. International Journal of Clinical Practice, 2013, 67, 1267-1282.	1.7	281
301	<i>î²</i> ell differentiation and regeneration in type 1 diabetes. Diabetes, Obesity and Metabolism, 2013, 15, 98-104.	4.4	21
302	Effects of vitamin D on antigen-specific and non-antigen-specific immune modulation: relevance for type 1 diabetes. Pediatric Diabetes, 2013, 14, 81-89.	2.9	37
303	Patient-Reported Frequency, Awareness And Patient-Physician Communication Of Hypoglycaemia In Belgium. Value in Health, 2013, 16, A159.	0.3	0
304	Unraveling the effects of 1,25(OH)2D3 on global gene expression in pancreatic islets. Journal of Steroid Biochemistry and Molecular Biology, 2013, 136, 68-79.	2.5	34
305	Cardiovascular risk factors and complications associated with albuminuria and impaired renal function in insulin-treated diabetes. Journal of Diabetes and Its Complications, 2013, 27, 370-375.	2.3	7
306	1α,25-Dihydroxyvitamin D3 and its analogs as modulators of human dendritic cells: A comparison dose-titration study. Journal of Steroid Biochemistry and Molecular Biology, 2013, 136, 160-165.	2.5	37

Chantal Mathieu

#	Article	IF	CITATIONS
307	How long should a long acting insulin analogue be?. Diabetes Research and Clinical Practice, 2013, 100, 170-172.	2.8	1
308	Repeated water emersions and domestication have no marked influence on stress physiology but modulate the abundance of several immune proteins in Eurasian perch. Fish and Shellfish Immunology, 2013, 34, 1649-1650.	3.6	0
309	Vitamin D and chronic obstructive pulmonary disease: hype or reality?. Lancet Respiratory Medicine,the, 2013, 1, 804-812.	10.7	43
310	Hypoglycaemia risk with insulin degludec compared with insulin glargine in type 2 and type 1 diabetes: a preâ€planned metaâ€analysis of phase 3 trials. Diabetes, Obesity and Metabolism, 2013, 15, 175-184.	4.4	309
311	Antigen-based vs. systemic immunomodulation in type 1 diabetes. Islets, 2013, 5, 53-66.	1.8	14
312	Glucagon-Like Peptide-1 Protects Human Islets against Cytokine-Mediated β-Cell Dysfunction and Death: A Proteomic Study of the Pathways Involved. Journal of Proteome Research, 2013, 12, 4193-4206.	3.7	27
313	Role of the Saturated Nonesterified Fatty Acid Palmitate in Beta Cell Dysfunction. Journal of Proteome Research, 2013, 12, 347-362.	3.7	43
314	SWITCHING FROM PREMIXED INSULIN TO BASAL–BOLUS INSULIN GLARGINE PLUS RAPID-ACTING INSULIN: THE ATLANTIC STUDY. Acta Clinica Belgica, 2013, 68, 28-33.	1.2	17
315	SGLT2-INHIBITORS: A NOVEL CLASS FOR THE TREATMENT OF TYPE 2 DIABETES INTRODUCTION OF SGLT2-INHIBITORS IN CLINICAL PRACTICE. Acta Clinica Belgica, 2013, 68, 287-293.	1.2	31
316	Influence of chronic comorbidity and medication on the efficacy of treatment in patients with diabetes in general practice. British Journal of General Practice, 2013, 63, e267-e273.	1.4	20
317	Analysis of Pregnancy Outcomes Using the New IADPSG Recommendation Compared with the Carpenter and Coustan Criteria in an Area with a Low Prevalence of Gestational Diabetes. International Journal of Endocrinology, 2013, 2013, 1-6.	1.5	65
318	Patient-reported outcomes among patients using exenatide twice daily or insulin in clinical practice in six European countries: the CHOICE prospective observational study. Health and Quality of Life Outcomes, 2013, 11, 217.	2.4	15
319	Gestational diabetes. Current Opinion in Obstetrics and Gynecology, 2013, 25, 462-467.	2.0	7
320	Comparison of insulin degludec with insulin glargine in insulinâ€naive subjects with TypeÂ2 diabetes: a 2â€year randomized, treatâ€toâ€target trial. Diabetic Medicine, 2013, 30, 1298-1304.	2.3	84
321	Effectiveness and tolerability of secondâ€line therapy with vildagliptin vs. other oral agents in type 2 diabetes: A realâ€life worldwide observational study (<scp>EDGE</scp>). International Journal of Clinical Practice, 2013, 67, 947-956.	1.7	54
322	ROS-induced autophagy in cancer cells assists in evasion from determinants of immunogenic cell death. Autophagy, 2013, 9, 1292-1307.	9.1	252
323	Phosphorylation of p27 <scp>^{KIP}</scp> ¹ homologs <scp>KRP</scp> 6 and 7 by <scp>SNF</scp> 1â€related protein kinase–1 links plant energy homeostasis and cell proliferation. Plant Journal, 2013, 75, 515-525.	5.7	52
324	Glucagonâ€like peptideâ€1: modulator of <i>β</i> â€cell dysfunction and death. Diabetes, Obesity and Metabolism, 2013, 15, 185-192.	4.4	22

#	Article	IF	CITATIONS
325	Minimal Functional β-Cell Mass in Intraportal Implants That Reduces Glycemic Variability in Type 1 Diabetic Recipients. Diabetes Care, 2013, 36, 3483-3488.	8.6	26
326	Efficacy and Safety of Insulin Degludec in a Flexible Dosing Regimen vs Insulin Glargine in Patients With Type 1 Diabetes (BEGIN: Flex T1): A 26-Week Randomized, Treat-to-Target Trial With a 26-Week Extension. Journal of Clinical Endocrinology and Metabolism, 2013, 98, 1154-1162.	3.6	193
327	Treatment outcomes after initiation of exenatide twice daily or insulin in clinical practice: 12-month results from CHOICE in six European countries. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 2013, 6, 171.	2.4	6
328	Resource use and costs of exenatide bid or insulin in clinical practice: the European CHOICE study. ClinicoEconomics and Outcomes Research, 2013, 5, 355.	1.9	4
329	Reversal of Hyperglycemia by Insulin-Secreting Rat Bone Marrow- and Blastocyst-Derived Hypoblast Stem Cell-Like Cells. PLoS ONE, 2013, 8, e63491.	2.5	9
330	Vitamin D action: lessons from VDR and Cyp27b1 null mice. Pediatric Endocrinology Reviews, 2013, 10 Suppl 2, 354-66.	1.2	11
331	Altered Expression of Key Players in Vitamin D Metabolism and Signaling in Malignant and Benign Thyroid Tumors. Journal of Histochemistry and Cytochemistry, 2012, 60, 502-511.	2.5	47
332	Straight from D-Heart. Current Opinion in Lipidology, 2012, 23, 17-23.	2.7	13
333	Insulin Degludec Versus Insulin Glargine in Insulin-Naive Patients With Type 2 Diabetes. Diabetes Care, 2012, 35, 2464-2471.	8.6	305
334	Pancreatic β-cells activate a JunB/ATF3-dependent survival pathway during inflammation. Oncogene, 2012, 31, 1723-1732.	5.9	38
335	The Vitamin D Receptor in Thyroid Development and Function. European Thyroid Journal, 2012, 1, 168-175.	2.4	14
336	Uremia Suppresses Immune Signal-Induced CYP27B1 Expression in Human Monocytes. American Journal of Nephrology, 2012, 36, 497-508.	3.1	34
337	High Doses of Vitamin D to Reduce Exacerbations in Chronic Obstructive Pulmonary Disease. Annals of Internal Medicine, 2012, 156, 105.	3.9	309
338	A novel pathway combining calreticulin exposure and ATP secretion in immunogenic cancer cell death. EMBO Journal, 2012, 31, 1062-1079.	7.8	641
339	Posttranslational Modifications of Proteins in Type 1 Diabetes: The Next Step in Finding the Cure?. Diabetes, 2012, 61, 1907-1914.	0.6	40
340	Extraskeletal Effects of Vitamin D. Endocrinology and Metabolism Clinics of North America, 2012, 41, 571-594.	3.2	44
341	Decreased miR-181a Expression in Monocytes of Obese Patients Is Associated with the Occurrence of Metabolic Syndrome and Coronary Artery Disease. Journal of Clinical Endocrinology and Metabolism, 2012, 97, E1213-E1218.	3.6	106
342	1,25-Dihydroxyvitamin D3 curtails the inflammatory and T cell stimulatory capacity of macrophages through an IL-10-dependent mechanism. Immunobiology, 2012, 217, 1292-1300.	1.9	148

#	Article	IF	CITATIONS
343	Insulin Degludec Allows for Flexible Daily Dosing in Type 1 Diabetes, Providing Equal Glycemic Control with Less Nocturnal Hypoglycemia than Insulin Glargine Over 52 Weeks. Canadian Journal of Diabetes, 2012, 36, S56-S57.	0.8	2
344	Prospectively Planned Meta-Analysis comparing Hypoglycemia Rates of Insulin Degludec with those of Insulin Glargine. Canadian Journal of Diabetes, 2012, 36, S16.	0.8	2
345	Differential Protein Pathways in 1,25-Dihydroxyvitamin D ₃ and Dexamethasone Modulated Tolerogenic Human Dendritic Cells. Journal of Proteome Research, 2012, 11, 941-971.	3.7	112
346	Death Protein 5 and p53-Upregulated Modulator of Apoptosis Mediate the Endoplasmic Reticulum Stress–Mitochondrial Dialog Triggering Lipotoxic Rodent and Human β-Cell Apoptosis. Diabetes, 2012, 61, 2763-2775.	0.6	118
347	Relation between diabetes, metformin treatment and the occurrence of malignancies in a Belgian primary care setting. Diabetes Research and Clinical Practice, 2012, 97, 331-336.	2.8	24
348	Glycated hemoglobin in pregnancies at increased risk for gestational diabetes mellitus. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2012, 161, 157-162.	1.1	12
349	Vitamin D supplementation during rehabilitation in COPD: a secondary analysis of a randomized trial. Respiratory Research, 2012, 13, 84.	3.6	88
350	The role of blood glucose monitoring in non-insulin treated type 2 diabetes: What is the evidence?. Primary Care Diabetes, 2012, 6, 179-185.	1.8	16
351	Low doses of anti-CD3, ciclosporin A and the vitamin D analogue, TX527, synergise to delay recurrence of autoimmune diabetes in an islet-transplanted NOD mouse model of diabetes. Diabetologia, 2012, 55, 2723-2732.	6.3	25
352	Vitamin D and Diabetes. Rheumatic Disease Clinics of North America, 2012, 38, 179-206.	1.9	51
353	Patients with Type 2 Diabetes Initiating Exenatide Twice Daily or Insulin in Clinical Practice: CHOICE Study. Diabetes Therapy, 2012, 3, 6.	2.5	8
354	Interleukin-1 Receptor-Associated Kinase-3 Is a Key Inhibitor of Inflammation in Obesity and Metabolic Syndrome. PLoS ONE, 2012, 7, e30414.	2.5	70
355	GLP1 and cancer: friend or foe?. Endocrine-Related Cancer, 2012, 19, F77-F88.	3.1	57
356	Air pollutionâ€associated procoagulant changes: the role of circulating microvesicles. Journal of Thrombosis and Haemostasis, 2012, 10, 96-106.	3.8	54
357	Deletion of C/EBP homologous protein (Chop) in C57Bl/6 mice dissociates obesity from insulin resistance. Diabetologia, 2012, 55, 1167-1178.	6.3	67
358	Reversal of autoimmune diabetes by restoration of antigen-specific tolerance using genetically modified Lactococcus lactis in mice. Journal of Clinical Investigation, 2012, 122, 1717-1725.	8.2	168
359	Decrease of miR-146b-5p in Monocytes during Obesity Is Associated with Loss of the Anti-Inflammatory but Not Insulin Signaling Action of Adiponectin. PLoS ONE, 2012, 7, e32794.	2.5	76
360	Gestational diabetes: overview of the new consensus screening strategy and diagnostic criteria. Acta Clinica Belgica, 2012, 67, 255-61.	1.2	12

#	Article	IF	CITATIONS
361	Oleate-Induced Beta Cell Dysfunction and Apoptosis: A Proteomic Approach to Glucolipotoxicity by an Unsaturated Fatty Acid. Journal of Proteome Research, 2011, 10, 3372-3385.	3.7	22
362	3. Vitamin D and the Immune System: Do It Yourself!. Translational Endocrinology & Metabolism, 2011, , 61-86.	0.2	0
363	Otelixizumab in the treatment of Type 1 diabetes mellitus. Immunotherapy, 2011, 3, 1303-1316.	2.0	13
364	PDB49 Resource Use in Patients with Type 2 Diabetes (T2D) Who Initiated Exenatide BID (EXBID) or Starter Insulin (INS) Therapy: 6-Month Data from Choice. Value in Health, 2011, 14, A480.	0.3	0
365	Physiological and proteomic evidences that domestication process differentially modulates the immune status of juvenile Eurasian perch (Perca fluviatilis) under chronic confinement stress. Fish and Shellfish Immunology, 2011, 31, 1113-1121.	3.6	41
366	Vitamin D in autoimmune, infectious and allergic diseases: A vital player?. Best Practice and Research in Clinical Endocrinology and Metabolism, 2011, 25, 617-632.	4.7	102
367	How can macroscopically normal peritoneum contribute to the pathogenesis of endometriosis?. Fertility and Sterility, 2011, 96, 697-699.	1.0	20
368	Vitamin D and diabetes: Its importance for beta cell and immune function. Molecular and Cellular Endocrinology, 2011, 347, 106-120.	3.2	166
369	1,25-Dihydroxyvitamin D3 and a superagonistic analog in combination with paclitaxel or suberoylanilide hydroxamic acid have potent antiproliferative effects on anaplastic thyroid cancer. Journal of Steroid Biochemistry and Molecular Biology, 2011, 124, 1-9.	2.5	31
370	Insulin degludec, an ultra-long-acting basal insulin, once a day or three times a week versus insulin glargine once a day in patients with type 2 diabetes: a 16-week, randomised, open-label, phase 2 trial. Lancet, The, 2011, 377, 924-931.	13.7	122
371	Arresting type 1 diabetes after diagnosis: GAD is not enough. Lancet, The, 2011, 378, 291-292.	13.7	12
372	Vitamin D Binding Protein Phenotypes Have An Impact On Vitamin D Substitution In COPD. , 2011, , .		0
373	Pdx1- and Ngn3-Cre-Mediated PLAG1 Expression in the Pancreas Leads to Endocrine Hormone Imbalances That Affect Glucose Metabolism. Cell Transplantation, 2011, 20, 1285-1297.	2.5	5
374	Sensor-augmented pump therapy lowers HbA1c in suboptimally controlled Type 1 diabetes; a randomized controlled trial. Diabetic Medicine, 2011, 28, 1158-1167.	2.3	151
375	Strategies for the prevention of autoimmune Type 1 diabetes. Diabetic Medicine, 2011, 28, 1141-1143.	2.3	16
376	The importance of glycemic control: how low should we go with HbA1c? Start early, go safe, go low. Journal of Diabetes and Its Complications, 2011, 25, 202-207.	2.3	17
377	Twoâ€dimensional gel proteome reference map of INSâ€1E cells. Proteomics, 2011, 11, 1365-1369.	2.2	10
378	Preservation of recall immunity in antiâ€CD3â€ŧreated recent onset type 1 diabetes patients. Diabetes/Metabolism Research and Reviews, 2011, 27, 925-927.	4.0	6

#	Article	IF	CITATIONS
379	1,25â€Dihydroxyvitamin D ₃ alters murine dendritic cell behaviour <i>in vitro</i> and <i>in vivo</i> . Diabetes/Metabolism Research and Reviews, 2011, 27, 933-941.	4.0	85
380	An integrated proteomics and genomics analysis to unravel a heterogeneous platelet secretion defect. Journal of Proteomics, 2011, 74, 902-913.	2.4	35
381	Vitamin D Deficiency and Chronic Obstructive Pulmonary Disease. Vitamins and Hormones, 2011, 86, 379-399.	1.7	53
382	Vitamin D and the immune system: Getting it right. IBMS BoneKEy, 2011, 8, 178-186.	0.0	22
383	Immune and cell therapy in type 1 diabetes: too little too late?. Expert Opinion on Biological Therapy, 2011, 11, 609-621.	3.1	2
384	Calcium Insufficiency Accelerates Type 1 Diabetes in Vitamin D Receptor-Deficient Nonobese Diabetic (NOD) Mice. Endocrinology, 2011, 152, 4620-4629.	2.8	14
385	The Vitamin D Analog, TX527, Promotes a Human CD4+CD25highCD127low Regulatory T Cell Profile and Induces a Migratory Signature Specific for Homing to Sites of Inflammation. Journal of Immunology, 2011, 186, 132-142.	0.8	126
386	STAT1 Is a Master Regulator of Pancreatic β-Cell Apoptosis and Islet Inflammation. Journal of Biological Chemistry, 2011, 286, 929-941.	3.4	144
387	Cytokines Tumor Necrosis Factor-α and Interferon-γ Induce Pancreatic β-Cell Apoptosis through STAT1-mediated Bim Protein Activation. Journal of Biological Chemistry, 2011, 286, 39632-39643.	3.4	96
388	Patients' Experiences with Patient-Centred Care are Associated with Documented outcome of Care Indicators for Diabetes: Findings from the Leuven Diabetes Project. International Journal of Care Pathways, 2011, 15, 65-75.	0.5	4
389	Contribution of Antibodies Against IA-2β and Zinc Transporter 8 to Classification of Diabetes Diagnosed Under 40 Years of Age. Diabetes Care, 2011, 34, 1760-1765.	8.6	81
390	Vitamin D Deficiency Is Not Good for You. Diabetes Care, 2011, 34, 1245-1246.	8.6	6
391	Vitamin D and Diabetes. , 2011, , 1825-1842.		Ο
392	Traffic Air Pollution and Oxidized LDL. PLoS ONE, 2011, 6, e16200.	2.5	65
393	Monitoring Modifiable Cardiovascular Risk in Type 2 Diabetes Care in General Practice. Medical Care, 2010, 48, 589-595.	2.4	3
394	Transient Epstein-Barr virus reactivation in CD3 monoclonal antibody-treated patients. Blood, 2010, 115, 1145-1155.	1.4	68
395	Biological Activity of CD-Ring Modified 1α,25-Dihydroxyvitamin D Analogues: C-Ring and Five-Membered D-Ring Analogues. Journal of Bone and Mineral Research, 2010, 15, 237-252.	2.8	45
396	Hyperglycaemic clamp test for diabetes risk assessment in IA-2-antibody-positive relatives of type 1 diabetic patients. Diabetologia, 2010, 53, 36-44.	6.3	23

#	Article	IF	CITATIONS
397	Four-year metabolic outcome of a randomised controlled CD3-antibody trial in recent-onset type 1 diabetic patients depends on their age and baseline residual beta cell mass. Diabetologia, 2010, 53, 614-623.	6.3	286
398	Vitamin D and diabetes: the devil is in the D-tails. Diabetologia, 2010, 53, 1545-1548.	6.3	17
399	Vitamin D insufficiency: implications for the immune system. Pediatric Nephrology, 2010, 25, 1597-1606.	1.7	89
400	Murine bone marrow chimeras developing autoimmunity after CTLA-4-blockade show an expansion of T regulatory cells with an activated cytokine profile. Immunology Letters, 2010, 133, 49-53.	2.5	6
401	Understanding dendritic cell biology and its role in immunological disorders through proteomic profiling. Proteomics - Clinical Applications, 2010, 4, 190-203.	1.6	8
402	Vitamin D Deficiency Correlates With Disease Severity In COPD. , 2010, , .		1
403	Vitamin D deficiency is highly prevalent in COPD and correlates with variants in the vitamin D-binding gene. Thorax, 2010, 65, 215-220.	5.6	379
404	Glycemic Control with Preprandial Versus Basal Insulin in Patients with Type 2 Diabetes Mellitus Poorly Controlled by Oral Antidiabetes Agents. Diabetes Technology and Therapeutics, 2010, 12, 135-141.	4.4	8
405	Air Pollution–Related Prothrombotic Changes in Persons with Diabetes. Environmental Health Perspectives, 2010, 118, 191-196.	6.0	109
406	Increased Î ² -Cell Mass by Islet Transplantation and PLAG1 Overexpression Causes Hyperinsulinemic Normoglycemia and Hepatic Insulin Resistance in Mice. Diabetes, 2010, 59, 1957-1965.	0.6	11
407	Crucial Role of Interferon-Î ³ in Experimental Autoimmune Prostatitis. Journal of Urology, 2010, 183, 1213-1220.	0.4	25
408	Real-Time Polymerase Chain Reaction. , 2010, , 87-105.		2
409	Vitamin D and Diabetes. Endocrinology and Metabolism Clinics of North America, 2010, 39, 419-446.	3.2	228
410	Novel Insights into the Global Proteome Responses of Insulin-Producing INS-1E Cells To Different Degrees of Endoplasmic Reticulum Stress. Journal of Proteome Research, 2010, 9, 5142-5152.	3.7	22
411	High Glucose Induces Dysfunction in Insulin Secretory Cells by Different Pathways: A Proteomic Approach. Journal of Proteome Research, 2010, 9, 6274-6287.	3.7	30
412	Human T lymphocytes are direct targets of 1,25-dihydroxyvitamin D3 in the immune system. Journal of Steroid Biochemistry and Molecular Biology, 2010, 121, 221-227.	2.5	188
413	Vitamin D: modulator of the immune system. Current Opinion in Pharmacology, 2010, 10, 482-496.	3.5	1,025
414	Start improving the quality of care for people with type 2 diabetes through a general practice support program: A cluster randomized trial. Diabetes Research and Clinical Practice, 2010, 88, 56-64.	2.8	37

#	Article	IF	CITATIONS
415	The effectiveness of hysteroscopy in improving pregnancy rates in subfertile women without other gynaecological symptoms: a systematic review. Human Reproduction Update, 2010, 16, 1-11.	10.8	214
416	Vitamin D: a pleiotropic hormone. Kidney International, 2010, 78, 140-145.	5.2	271
417	Pharmacokinetics and Antibody Responses to the CD3 Antibody Otelixizumab Used in the Treatment of Type 1 Diabetes. Journal of Clinical Pharmacology, 2010, 50, 1238-1248.	2.0	36
418	The effectiveness of reproductive surgery in the treatment of female infertility: facts, views and vision. Facts, Views & Vision in ObGyn, 2010, 2, 232-52.	1.1	6
419	A Comparison Between Simplified and Intensive Dose-Titration Algorithms Using AIR Inhaled Insulin for Insulin-Naive Patients with Type 2 Diabetes in a Randomized Noninferiority Trial. Diabetes Technology and Therapeutics, 2009, 11, S-53-S-61.	4.4	7
420	Graves Hyperthyroidism After Stopping Immunosuppressive Therapy in Type 1 Diabetic Islet Cell Recipients With Pretransplant TPO Autoantibodies. Diabetes Care, 2009, 32, 1817-1819.	8.6	19
421	Vitamin D Beyond Bones in Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2009, 179, 630-636.	5.6	173
422	Differences in Baseline Lymphocyte Counts and Autoreactivity Are Associated With Differences in Outcome of Islet Cell Transplantation in Type 1 Diabetic Patients. Diabetes, 2009, 58, 2267-2276.	0.6	96
423	Type 2 Diabetes in Primary Care in Belgium: Need for Structured Shared Care. Experimental and Clinical Endocrinology and Diabetes, 2009, 117, 367-372.	1.2	31
424	Two-Year Efficacy and Safety of AIR Inhaled Insulin in Patients with Type 1 Diabetes: An Open-Label Randomized Controlled Trial. Diabetes Technology and Therapeutics, 2009, 11, S-5-S-16.	4.4	19
425	Interdisciplinary diabetes care teams operating on the interface between primary and specialty care are associated with improved outcomes of care: findings from the Leuven Diabetes Project. BMC Health Services Research, 2009, 9, 179.	2.2	52
426	Implication of cortisol/glucocorticoid receptor in the immune response after an acute stress in Eurasian perch. Comparative Biochemistry and Physiology Part A, Molecular & Integrative Physiology, 2009, 154, S2.	1.8	0
427	OR.53. Synergistic Modulation of Human DC Phenotype and Function by Vitamin D Analogue and Histone Deacetylase Inhibitor. Clinical Immunology, 2009, 131, S23-S24.	3.2	0
428	Interferon regulatory factor-1 is a key transcription factor in murine beta cells under immune attack. Diabetologia, 2009, 52, 2374-2384.	6.3	24
429	Proteome analysis demonstrates profound alterations in human dendritic cell nature by TX527, an analogue of vitamin D. Proteomics, 2009, 9, 3752-3764.	2.2	51
430	Is vitamin D deficiency involved in the immune reconstitution inflammatory syndrome?. AIDS Research and Therapy, 2009, 6, 4.	1.7	18
431	Barriers and facilitators to evidence based care of type 2 diabetes patients: experiences of general practitioners participating to a quality improvement program. Implementation Science, 2009, 4, 41.	6.9	42
432	Relevance of cytotoxic alloreactivity under different immunosuppressive regimens in clinical islet cell transplantation. Clinical and Experimental Immunology, 2009, 156, 141-148.	2.6	41

#	Article	IF	CITATIONS
433	The scientific evidence: vildagliptin and the benefits of islet enhancement. Diabetes, Obesity and Metabolism, 2009, 11, 9-17.	4.4	24
434	Evidence that Norflurazon Affects Chloroplast Lipid Unsaturation in Soybean Leaves (Glycine maxL.). Journal of Agricultural and Food Chemistry, 2009, 57, 11434-11440.	5.2	15
435	Prevalence and impact on quality of life of peripheral neuropathy with or without neuropathic pain in type 1 and type 2 diabetic patients attending hospital outpatients clinics. Diabetes and Metabolism, 2009, 35, 206-213.	2.9	308
436	Insulin treatment in IA-2A-positive relatives of type 1 diabetic patients. Diabetes and Metabolism, 2009, 35, 319-327.	2.9	35
437	Impact of vitamin D receptor activity on experimental autoimmune prostatitis. Journal of Autoimmunity, 2009, 32, 140-148.	6.5	17
438	Polymorphisms in innate immunity genes predispose to bacteremia and death in the medical intensive care unit*. Critical Care Medicine, 2009, 37, 192-e3.	0.9	130
439	INSULIN DETEMIR IN ROUTINE CLINICAL PRACTICE: A 26-WEEK FOLLOW-UP IN TYPE 1 DIABETIC PATIENTS FROM THE BELGIAN PREDICTIVE COHORT. Acta Clinica Belgica, 2009, 64, 49-55.	1.2	9
440	Diabetes and Peripheral Vascular Disease. Acta Chirurgica Belgica, 2009, 109, 587-594.	0.4	63
441	Functional β-Cell Mass and Insulin Sensitivity Is Decreased in Insulin-Independent Pancreas-Kidney Recipients. Transplantation, 2009, 87, 402-407.	1.0	18
442	Arabidopsis monomeric G-proteins, markers of early and late events in cell differentiation. International Journal of Developmental Biology, 2009, 53, 177-185.	0.6	5
443	Antiproliferative and calcemic actions of trans-decalin CD-ring analogs of 1,25-dihydroxyvitamin D3. Anticancer Research, 2009, 29, 3579-84.	1.1	8
444	A cluster randomized trial to improve adherence to evidence-based guidelines on diabetes and reduce clinical inertia in primary care physicians in Belgium: study protocol [NTR 1369]. Implementation Science, 2008, 3, 42.	6.9	14
445	Type 2 diabetes: Gaining insight into the disease process using proteomics. Proteomics - Clinical Applications, 2008, 2, 312-326.	1.6	7
446	Proteinâ€induced changes during the maturation process of human dendritic cells: A 2â€D DIGE approach. Proteomics - Clinical Applications, 2008, 2, 1349-1360.	1.6	12
447	Regulation of vitamin D homeostasis: implications for the immune system. Nutrition Reviews, 2008, 66, S125-S134.	5.8	116
448	Reaching glycaemic targets while minimizing hypoglycaemia in insulin-treated type 2 diabetes patients. Diabetes, Obesity and Metabolism, 2008, 10, 14-23.	4.4	5
449	The development of atopic dermatitis is independent of Immunoglobulin E upâ€regulation in the K14â€ILâ€4 SKH1 transgenic mouse model. Clinical and Experimental Allergy, 2008, 38, 1367-1380.	2.9	28
450	Sa.104. The Effects of TX527, a 1,25-Dihydroxyvitamin D3 Analogue, on Human Dendritic Cells: A Proteomic Approach. Clinical Immunology, 2008, 127, S114-S115.	3.2	0

#	Article	IF	CITATIONS
451	Sa.105. Immunomodulatory Effects of TX527, a Less Calcemic Vitamin D Analog, on Human Synchronized T Cells: a Proteomic Approach. Clinical Immunology, 2008, 127, S115.	3.2	0
452	T-cell mediated late increase in bronchial tone after allergen provocation in a murine asthma model. Clinical Immunology, 2008, 128, 248-258.	3.2	10
453	Vitamin D signaling in immune-mediated disorders: Evolving insights and therapeutic opportunities. Molecular Aspects of Medicine, 2008, 29, 376-387.	6.4	83
454	The plant CDK inhibitor NtKIS1a interferes with dedifferentiation, is specifically down regulated during development and interacts with a JAB1 homolog. Plant Science, 2008, 175, 513-523.	3.6	10
455	Effect of recombinant human TNF–binding protein-1 and GnRH antagonist on mRNA expression of inflammatory cytokines and adhesion and growth factors in endometrium and endometriosis tissues in baboons. Fertility and Sterility, 2008, 89, 1306-1313.	1.0	20
456	Endometrial and peritoneal expression of aromatase, cytokines, and adhesion factors in women with endometriosis. Fertility and Sterility, 2008, 89, 301-310.	1.0	130
457	Double-Stranded RNA Induces Pancreatic Â-Cell Apoptosis by Activation of the Toll-Like Receptor 3 and Interferon Regulatory Factor 3 Pathways. Diabetes, 2008, 57, 1236-1245.	0.6	91
458	Proteomics as a tool to discover biomarkers for the prediction of diabetic complications. Expert Opinion on Medical Diagnostics, 2008, 2, 277-287.	1.6	2
459	Patients' Perceptions of Subcutaneous Insulin in the OPTIMIZE Study: A Multicenter Follow-Up Study. Diabetes Technology and Therapeutics, 2008, 10, 25-38.	4.4	27
460	Vitamin D and Human Health: Lessons from Vitamin D Receptor Null Mice. Endocrine Reviews, 2008, 29, 726-776.	20.1	1,461
461	Unaltered Diabetes Presentation in NOD Mice Lacking the Vitamin D Receptor. Diabetes, 2008, 57, 269-275.	0.6	75
462	Pancreatic Duct Cells in Human Islet Cell Preparations Are a Source of Angiogenic Cytokines Interleukin-8 and Vascular Endothelial Growth Factor. Diabetes, 2008, 57, 2128-2136.	0.6	45
463	Initiation and execution of lipotoxic ER stress in pancreatic β-cells. Journal of Cell Science, 2008, 121, 2308-2318.	2.0	512
464	DISORDERS OF GLUCOSE METABOLISM IN HUMAN IMMUNODEFICIENCY VIRUS-INFECTED PATIENTS. Acta Clinica Belgica, 2008, 63, 227-234.	1.2	0
465	Cytokine signalling in the β-cell: a dual role for IFNγ. Biochemical Society Transactions, 2008, 36, 328-333.	3.4	60
466	Comparison of Sirolimus Alone With Sirolimus Plus Tacrolimus in Type 1 Diabetic Recipients of Cultured Islet Cell Grafts. Transplantation, 2008, 85, 256-263.	1.0	33
467	Late CD8+ T Cell-Dependent Xenoantibody Production in Innate Tolerant Nude Rats After Hamster Islet Grafting But Not After Hamster Heart Grafting. Transplantation, 2008, 85, 1489-1495.	1.0	4
468	Occurrence of Autoimmunity After Xenothymus Transplantation in T-Cell-Deficient Mice Depends on the Thymus Transplant Technique. Transplantation, 2008, 85, 640-644.	1.0	8

#	Article	IF	CITATIONS
469	Vildagliptin: a new oral treatment for type 2 diabetes mellitus. Vascular Health and Risk Management, 2008, Volume 4, 1349-1360.	2.3	41
470	Cellular Islet Autoimmunity Associates with Clinical Outcome of Islet Cell Transplantation. PLoS ONE, 2008, 3, e2435.	2.5	172
471	Other Forms of Immunosuppression. , 2008, , 333-349.		2
472	Light and Oxygen Are Not Required for Harpin-induced Cell Death. Journal of Biological Chemistry, 2007, 282, 37556-37566.	3.4	29
473	Mechanism and Potential of the Growth-Inhibitory Actions of Vitamin D and Analogs. Current Medicinal Chemistry, 2007, 14, 1893-1910.	2.4	96
474	Two Caucasian Families with the Hepatocyte Nuclear Factor-1Alpha Mutation Tyr218Cys. Experimental and Clinical Endocrinology and Diabetes, 2007, 115, 62-64.	1.2	4
475	Deletion of STAT-1 Pancreatic Islets Protects Against Streptozotocin-Induced Diabetes and Early Graft Failure but Not Against Late Rejection. Diabetes, 2007, 56, 2169-2173.	0.6	48
476	Central Insulin Regulates Heart Rate and Arterial Blood Flow. Diabetes, 2007, 56, 2872-2877.	0.6	44
477	Proteomics Analysis of Cytokine-induced Dysfunction and Death in Insulin-producing INS-1E Cells. Molecular and Cellular Proteomics, 2007, 6, 2180-2199.	3.8	73
478	Vitamin D ₃ and the immune system: maintaining the balance in health and disease. Nutrition Research Reviews, 2007, 20, 106-118.	4.1	60
479	Cell Loss during Pseudoislet Formation Hampers Profound Improvements in Islet Lentiviral Transduction Efficacy for Transplantation Purposes. Cell Transplantation, 2007, 16, 527-537.	2.5	17
480	The Role of Vitamin D in the Pathogenesis of NOD Mouse Diabetes. Immunology, Endocrine and Metabolic Agents in Medicinal Chemistry, 2007, 7, 203-209.	0.5	0
481	High Rate of Charcot Foot Attacks Early After Simultaneous Pancreas???Kidney Transplantation. Transplantation, 2007, 83, 245-246.	1.0	35
482	Monocytes from type 2 diabetic patients have a pro-inflammatory profile. Diabetes Research and Clinical Practice, 2007, 77, 47-57.	2.8	338
483	The Vitamin D analogue TX 527 blocks NF-ήB activation in peripheral blood mononuclear cells of patients with Crohn's disease. Journal of Steroid Biochemistry and Molecular Biology, 2007, 103, 51-60.	2.5	78
484	1α,25-Dihydroxyvitamin D3-induced down-regulation of the checkpoint proteins, Chk1 and Claspin, is mediated by the pocket proteins p107 and p130. Journal of Steroid Biochemistry and Molecular Biology, 2007, 103, 411-415.	2.5	14
485	Immune regulation of 11±-hydroxylase in murine peritoneal macrophages: Unravelling the IFN13 pathway. Journal of Steroid Biochemistry and Molecular Biology, 2007, 103, 567-571.	2.5	67
486	Novel insights in the immune function of the vitamin D system: Synergism with interferon-beta. Journal of Steroid Biochemistry and Molecular Biology, 2007, 103, 546-551.	2.5	52

#	Article	IF	CITATIONS
487	Lack of Respiratory Chain Complex I Impairs Alternative Oxidase Engagement and Modulates Redox Signaling during Elicitor-Induced Cell Death in Tobacco. Plant Cell, 2007, 19, 640-655.	6.6	122
488	Quality indicators for type-2 diabetes care in practice guidelines: An example from six European countries. Primary Care Diabetes, 2007, 1, 17-23.	1.8	35
489	PDB7 ADDITION OF INHALED HUMAN INSULIN AS AN OPTION FOR PATIENTS WITHTYPE 2 DIABETES UNCONTROLLED ON ORAL ANTIDIABETICS SHOULD AVOID COMPLICATIONS PREDICTED BY EAGLE MODEL. Value in Health, 2007, 10, A255.	0.3	0
490	Modified aquaporin 5 expression and distribution in submandibular glands from NOD mice displaying autoimmune exocrinopathy. Arthritis and Rheumatism, 2007, 56, 2566-2574.	6.7	46
491	Therapy with the hsp60 peptide DiaPep277â,,¢ in C-peptide positive type 1 diabetes patients. Diabetes/Metabolism Research and Reviews, 2007, 23, 269-275.	4.0	77
492	Economic aspects of diabetic foot care in a multidisciplinary setting: a review. Diabetes/Metabolism Research and Reviews, 2007, 23, 339-347.	4.0	61
493	The age at diagnosis of type 1 diabetes continues to decrease in Belgian boys but not in girls: a 15â€year survey. Diabetes/Metabolism Research and Reviews, 2007, 23, 637-643.	4.0	15
494	The vitamin D receptor geneFokI polymorphism: Functional impact on the immune system. European Journal of Immunology, 2007, 37, 395-405.	2.9	221
495	Identification of prediabetes in first-degree relatives at intermediate risk of type I diabetes. Clinical and Experimental Immunology, 2007, 149, 243-250.	2.6	8
496	Antihyperglycaemic therapy in elderly patients with type 2 diabetes: potential role of incretin mimetics and DPP-4 inhibitors. International Journal of Clinical Practice, 2007, 61, 29-37.	1.7	30
497	Neuropeptides of the islets of Langerhans: A peptidomics study. General and Comparative Endocrinology, 2007, 152, 231-241.	1.8	51
498	Adiponectin levels do not predict clinical onset of type 1 diabetes in antibody-positive relatives. Diabetologia, 2007, 50, 2143-2146.	6.3	8
499	Inhaled insulin: gone with the wind?. Diabetologia, 2007, 51, 1-5.	6.3	18
500	Comparative therapeutic effects of orally administered 1,25-dihydroxyvitamin D3 and 1alpha-hydroxyvitamin D3 on type-1 diabetes in non-obese diabetic mice fed a normal-calcaemic diet. Clinical and Experimental Immunology, 2007, 151, 76-85.	2.6	37
501	Hypercalciëmie: soms een samengesteld probleem. Tijdschrift Voor Geneeskunde, 2007, 63, 482-484.	0.0	0
502	Kan de progressie van diabetes mellitus type 2 worden beÃ⁻nvloed?. Tijdschrift Voor Geneeskunde, 2007, 63, 225-231.	0.0	0
503	Immune Regulation of 25-Hydroxyvitamin-D3-1α-Hydroxylase in Human Monocytes. Journal of Bone and Mineral Research, 2006, 21, 37-47.	2.8	222
504	Quantification of chemokines by real-time reverse transcriptase PCR: applications in type 1 diabetes. Expert Review of Molecular Diagnostics, 2006, 6, 51-64.	3.1	9

#	Article	IF	CITATIONS
505	Correlation between beta cell mass and glycemic control in type 1 diabetic recipients of islet cell graft. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 17444-17449.	7.1	166
506	Vitamin D resistance. Best Practice and Research in Clinical Endocrinology and Metabolism, 2006, 20, 627-645.	4.7	41
507	Increased peritoneal and endometrial gene expression of biologically relevant cytokines and growth factors during the menstrual phase in women with endometriosis. Fertility and Sterility, 2006, 85, 1667-1675.	1.0	128
508	Vitamin D and cancer. Journal of Steroid Biochemistry and Molecular Biology, 2006, 102, 156-162.	2.5	194
509	Identification of novel and recurrent glucokinase mutations in Belgian and Luxembourg maturity onset diabetes of the young patients. Clinical Genetics, 2006, 70, 355-359.	2.0	9
510	Involvement of 4-1BB (CD137)-4-1BBligand interaction in the modulation of CD4+ T cell-mediated inflammatory colitis. Clinical and Experimental Immunology, 2006, 143, 228-236.	2.6	25
511	Type 1 diabetes: entering the proteomic era. Expert Review of Proteomics, 2006, 3, 223-236.	3.0	11
512	How should HbA1c measurements be reported?. Diabetologia, 2006, 49, 7-10.	6.3	36
513	Immune Regulation of 25-Hydroxyvitamin D-1α-Hydroxylase in Human Monocytic THP1 Cells: Mechanisms of Interferon-γ-Mediated Induction. Journal of Clinical Endocrinology and Metabolism, 2006, 91, 3566-3574.	3.6	75
514	Post-transplant lymphoma of the pancreatic allograft in a kidney-pancreas transplant recipient: a misleading presentation. Nephrology Dialysis Transplantation, 2006, 21, 3306-3310.	0.7	7
515	CCL27 is a critical factor for the development of atopic dermatitis in the keratin-14 IL-4 transgenic mouse model. International Immunology, 2006, 18, 1233-1242.	4.0	51
516	Stimulation of A2A-adenosine receptors after myocardial infarction suppresses inflammatory activation and attenuates contractile dysfunction in the remote left ventricle. American Journal of Physiology - Heart and Circulatory Physiology, 2006, 290, H1410-H1418.	3.2	28
517	Hepatocellular Neoplasms Induced by Low-Number Pancreatic Islet Transplants in Autoimmune Diabetic BB/Pfd Rats. Cancer Research, 2006, 66, 1833-1843.	0.9	56
518	IL-12 Contributes to Allergen-Induced Airway Inflammation in Experimental Asthma. Journal of Immunology, 2006, 177, 6460-6470.	0.8	71
519	Development and Validation of the Economic Assessment of Glycemic Control and Long-Term Effects of Diabetes (EAGLE) Model. Diabetes Technology and Therapeutics, 2006, 8, 219-236.	4.4	42
520	Inhaled human insulin ((insulin human [rDNA origin]) Inhalation Powder) in diabetes mellitus. Expert Opinion on Drug Metabolism and Toxicology, 2006, 2, 779-791.	3.3	2
521	IL-10- and IL-12-Independent Down-Regulation of Allergic Sensitization by Stimulation of CD40 Signaling. Journal of Immunology, 2006, 177, 5138-5144.	0.8	14
522	Survival Benefits of Intensive Insulin Therapy in Critical Illness. Diabetes, 2006, 55, 1096-1105.	0.6	250

#	Article	IF	CITATIONS
523	Immunomodulation by 1,25-dihydroxyvitamin D3: therapeutic implications in hemodialysis and renal transplantation. Clinical Nephrology, 2006, 66, 275-283.	0.7	32
524	Regulatory Cells, Th1/Th2 Unbalance, and Antibody-Induced Chronic Rejection in Operational Tolerance Induced by Donor-Specific Blood Transfusion. Transplantation, 2005, 79, S25-S27.	1.0	31
525	Inhibitory and Stimulatory Effects of Cyclosporine A on the Development of Regulatory T Cells In Vivo. Transplantation, 2005, 79, 1073-1077.	1.0	74
526	Promoting targeted screening for Type 2 diabetes mellitus: the contribution of community pharmacists. Diabetic Medicine, 2005, 22, 812-813.	2.3	13
527	The disease progression in the keratin 14 IL-4-transgenic mouse model of atopic dermatitis parallels the up-regulation of B cell activation molecules, proliferation and surface and serum IgE. Clinical and Experimental Immunology, 2005, 142, 21-30.	2.6	22
528	1α,25-Dihydroxyvitamin D3 modulates the murine antibody response to pneumococcal capsular polysaccharide serotype 3 through IL-12. European Journal of Immunology, 2005, 35, 1841-1848.	2.9	4
529	Critical review of oral drug treatments for diabetic neuropathic pain—clinical outcomes based on efficacy and safety data from placebo-controlled and direct comparative studies. Diabetes/Metabolism Research and Reviews, 2005, 21, 231-240.	4.0	46
530	Combined positivity for HLA DQ2/DQ8 and IA-2 antibodies defines population at high risk of developing type 1 diabetes. Diabetologia, 2005, 48, 687-694.	6.3	41
531	Vitamin D and diabetes. Diabetologia, 2005, 48, 1247-1257.	6.3	550
532	Diabetes and pregnancy: beyond glucose?. Diabetologia, 2005, 48, 1714-1715.	6.3	1
533	Blockade of CTLA-4 (CD152) enhances the murine antibody response to pneumococcal capsular polysaccharides. Journal of Leukocyte Biology, 2005, 78, 1060-1069.	3.3	5
534	Characterization of the Condensin Component Cnap1 and Protein Kinase Melk as Novel E2F Target Genes Down-regulated by 1,25-Dihydroxyvitamin D3. Journal of Biological Chemistry, 2005, 280, 37319-37330.	3.4	43
535	Disruption of the Â-Interferon Signaling Pathway at the Level of Signal Transducer and Activator of Transcription-1 Prevents Immune Destruction of Â-cells. Diabetes, 2005, 54, 2396-2403.	0.6	95
536	Early Presence of Regulatory Cells in Transplanted Rats Rendered Tolerant by Donor-Specific Blood Transfusion. Journal of Immunology, 2005, 175, 4963-4970.	0.8	33
537	Targeting the NAD7 Subunit to Mitochondria Restores a Functional Complex I and a Wild Type Phenotype in the Nicotiana sylvestris CMS II Mutant Lacking nad7. Journal of Biological Chemistry, 2005, 280, 25994-26001.	3.4	84
538	Toll-like Receptor 3 and STAT-1 Contribute to Double-stranded RNA+ Interferon-Î ³ -induced Apoptosis in Primary Pancreatic Î ² -Cells. Journal of Biological Chemistry, 2005, 280, 33984-33991.	3.4	140
539	1,25-Dihydroxyvitamin D3 Modulates Expression of Chemokines and Cytokines in Pancreatic Islets: Implications for Prevention of Diabetes in Nonobese Diabetic Mice. Endocrinology, 2005, 146, 1956-1964.	2.8	185
540	Pre-diabetes essential action: a European perspective. Diabetes and Metabolism, 2005, 31, 606-620.	2.9	58

#	Article	IF	CITATIONS
541	Feasibility, Safety, and Efficacy of Percutaneous Transhepatic Injection of β-Cell Grafts. Journal of Vascular and Interventional Radiology, 2005, 16, 1693-1697.	0.5	26
542	1α,25-Dihydroxyvitamin D3 restores thymocyte apoptosis sensitivity in non-obese diabetic (NOD) mice through dendritic cells. Journal of Autoimmunity, 2005, 24, 281-289.	6.5	32
543	Immunoregulation by 1,25-dihydroxyvitamin D3: Basic concepts. Journal of Steroid Biochemistry and Molecular Biology, 2005, 97, 93-101.	2.5	743
544	Mechanisms for the selective action of Vitamin D analogs. Journal of Steroid Biochemistry and Molecular Biology, 2005, 97, 21-30.	2.5	53
545	Validation of real-time RT-PCR assays for mRNA quantification in baboons. Cytokine, 2005, 31, 454-458.	3.2	22
546	Vitamin D and type 1 diabetes mellitus: state of the art. Trends in Endocrinology and Metabolism, 2005, 16, 261-266.	7.1	201
547	Role of CD4+ and CD8+ T cells in the rejection of heart or islet xenografts in recipients with xenotolerance in the innate immune compartment. Transplantation Proceedings, 2005, 37, 516-517.	0.6	4
548	Insulin Needs after CD3-Antibody Therapy in New-Onset Type 1 Diabetes. New England Journal of Medicine, 2005, 352, 2598-2608.	27.0	1,028
549	Vitamin D and Diabetes. , 2005, , 1763-1778.		0
550	Regulation of Cytokines and Immune Function by 1,25-Dihydroxyvitamin D3 and Its Analogs. Oxidative Stress and Disease, 2005, , .	0.3	0
551	The sunshine hormone vitamin D and its association with type 1 diabetes. Discovery Medicine, 2005, 5, 399-402.	0.5	1
552	The Effects of 1α,25-Dihydroxyvitamin D3 on the Expression of DNA Replication Genes. Journal of Bone and Mineral Research, 2004, 19, 133-146.	2.8	66
553	DIABETIC MANAGEMENT IN HIGH RISK PATIENTS (PREGNANCY, INSULIN PUMPS). Acta Clinica Belgica, 2004, 59, 173-181.	1.2	4
554	Â-Cell Transplantation Restores Metabolic Control and Quality of Life in a Patient With Subcutaneous Insulin Resistance. Diabetes Care, 2004, 27, 2243-2244.	8.6	15
555	Early up-regulation of Th2 cytokines and late surge of Th1 cytokines in an atopic dermatitis model. Clinical and Experimental Immunology, 2004, 138, 375-387.	2.6	136
556	Can we reduce hypoglycaemia with insulin detemir?. International Journal of Obesity, 2004, 28, S35-S40.	3.4	16
557	Combined 'En Bloc' Liver and Pancreas Transplantation in Patients with Liver Disease and Type 1 Diabetes Mellitus. American Journal of Transplantation, 2004, 4, 1921-1927.	4.7	24
558	Monocytic Expression Behavior of Cytokines in Diabetic Patients upon Inflammatory Stimulation. Annals of the New York Academy of Sciences, 2004, 1037, 74-78.	3.8	22

#	Article	IF	CITATIONS
559	1,25-Dihydroxyvitamin D3Alters the Profile of Bone Marrow-Derived Dendritic Cells of NOD Mice. Annals of the New York Academy of Sciences, 2004, 1037, 186-192.	3.8	36
560	Vitamin D deficiency in early life accelerates Type 1 diabetes in non-obese diabetic mice. Diabetologia, 2004, 47, 451-462.	6.3	196
561	Human pancreatic duct cells can produce tumour necrosis factor-α that damages neighbouring beta cells and activates dendritic cells. Diabetologia, 2004, 47, 998-1008.	6.3	39
562	NOD macrophages produce high levels of inflammatory cytokines upon encounter of apoptotic or necrotic cells. Journal of Autoimmunity, 2004, 23, 9-15.	6.5	46
563	lα,25-Dihydroxyvitamin D3 or analogue treated dendritic cells modulate human autoreactive T cells via the selective induction of apoptosis. Journal of Autoimmunity, 2004, 23, 233-239.	6.5	141
564	Microarray analysis of 11±,25-dihydroxyvitamin D3-treated MC3T3-E1 cells. Journal of Steroid Biochemistry and Molecular Biology, 2004, 89-90, 405-407.	2.5	27
565	Vitamin D and 1,25-dihydroxyvitamin D3 as modulators in the immune system. Journal of Steroid Biochemistry and Molecular Biology, 2004, 89-90, 449-452.	2.5	92
566	Regulation of 25-hydroxyvitamin d-1α-hydroxylase by IFNγ in human monocytic THP1 cells. Journal of Steroid Biochemistry and Molecular Biology, 2004, 89-90, 453-455.	2.5	18
567	NOD bone marrow-derived dendritic cells are modulated by analogs of 1,25-dihydroxyvitamin D3. Journal of Steroid Biochemistry and Molecular Biology, 2004, 89-90, 457-459.	2.5	31
568	Early Accumulation of Interferon-?? in Grafts Tolerized by Donor-Specific Blood Transfusion: Friend or Enemy?. Transplantation, 2004, 78, 1747-1755.	1.0	9
569	HIGH-DOSE CALCINEURIN INHIBITOR BLOCKS THE GENERATION OF REGULATORY CELLS, WHEREAS LOW-DOSE PROMOTES THEIR DEVELOPMENT Transplantation, 2004, 78, 71.	1.0	0
570	Vitamin D3 in Control of Immune Response. , 2004, , 145-161.		0
571	Rosiglitazon in de behandeling van diabetes mellitus type 2: stand van zaken. Tijdschrift Voor Geneeskunde, 2004, 60, 262-271.	0.0	0
572	Eilandjestransplantatie: huidige inzichten en toekomstperspectieven. Tijdschrift Voor Geneeskunde, 2004, 60, 597-602.	0.0	0
573	Defective Activation-Induced Cell Death in NOD T Lymphocytes. Annals of the New York Academy of Sciences, 2003, 1005, 176-177.	3.8	13
574	Hen Egg White Lysozyme Vaccination Induces Acute Shock in NOD Mice. Annals of the New York Academy of Sciences, 2003, 1005, 215-217.	3.8	2
575	Diabetic ketoacidosis. Reviews in Endocrine and Metabolic Disorders, 2003, 4, 159-166.	5.7	36
576	IL-1β and IFN-γ induce the expression of diverse chemokines and IL-15 in human and rat pancreatic islet cells, and in islets from pre-diabetic NOD mice. Diabetologia, 2003, 46, 255-266.	6.3	184

#	Article	IF	CITATIONS
577	Prevention of primary non-function of islet xenografts in autoimmune diabetic NOD mice by anti-inflammatory agents. Diabetologia, 2003, 46, 1115-1123.	6.3	41
578	Analogs of 1α,25â€dihydroxyvitamin D ₃ as pluripotent immunomodulators. Journal of Cellular Biochemistry, 2003, 88, 223-226.	2.6	84
579	Markers for cardiovascular disease in monozygotic twins discordant for the use of third-generation oral contraceptives. Journal of Human Hypertension, 2003, 17, 481-485.	2.2	3
580	Paradoxical early upregulation of intragraft Th1 cytokines is associated with graft acceptance following donor-specific blood transfusion. Transplant International, 2003, 16, 179-185.	1.6	13
581	Metabolic, Endocrine, and Immune Effects of Stress Hyperglycemia in a Rabbit Model of Prolonged Critical Illness. Endocrinology, 2003, 144, 5329-5338.	2.8	214
582	Break of tolerance via donor-specific blood transfusion by high doses of steroids: a differential effect after intestinal transplantation and heart transplantation. Transplantation Proceedings, 2003, 35, 3153-3155.	0.6	11
583	Defect in activation-induced cell death in non-obese diabetic (NOD) T lymphocytes. Journal of Autoimmunity, 2003, 20, 219-226.	6.5	53
584	Combination of a 1,25-dihydroxyvitamin D3 analog and a bisphosphonate prevents experimental autoimmune encephalomyelitis and preserves bone. Bone, 2003, 32, 397-404.	2.9	53
585	Progesterone in gestational diabetes mellitus: guilty or not guilty?. Trends in Endocrinology and Metabolism, 2003, 14, 54-56.	7.1	63
586	Acute Shock Induced by Antigen Vaccination in NOD Mice. Diabetes, 2003, 52, 335-341.	0.6	26
587	Leaf Mitochondria Modulate Whole Cell Redox Homeostasis, Set Antioxidant Capacity, and Determine Stress Resistance through Altered Signaling and Diurnal Regulation. Plant Cell, 2003, 15, 1212-1226.	6.6	492
588	Prevalence and Predictors of Sexual Dysfunction in Patients With Type 1 Diabetes. Diabetes Care, 2003, 26, 409-414.	8.6	193
589	Interleukin-17 Orchestrates the Granulocyte Influx into Airways after Allergen Inhalation in a Mouse Model of Allergic Asthma. American Journal of Respiratory Cell and Molecular Biology, 2003, 28, 42-50.	2.9	359
590	Regulatory cell-mediated tolerance does not protect against chronic rejection. Transplantation, 2003, 76, 588-596.	1.0	37
591	Prospects for Vitamin D receptor Modulators as Candidate Drugs for Cancer and (Auto)immune Diseases. Recent Results in Cancer Research, 2003, 164, 353-356.	1.8	17
592	Vitamin D Effects on Cell Differentiation and Proliferation. , 2003, , 638-645.		0
593	The use of real-time reverse transcriptase PCR for the quantification of cytokine gene expression. Journal of Biomolecular Techniques, 2003, 14, 33-43.	1.5	265
594	Sexual Dysfunction in Women With Type 1 Diabetes: A controlled study. Diabetes Care, 2002, 25, 672-677.	8.6	229

#	Article	IF	CITATIONS
595	A Murine Interleukin-4-Ig Fusion Protein Regulates the Expression of Th1- and Th2-Specific Cytokines in the Pancreas of NOD Mice. Hormone and Metabolic Research, 2002, 34, 561-569.	1.5	5
596	Relation between Disease Phenotype and HLA-DQ Genotype in Diabetic Patients Diagnosed in Early Adulthood. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 2597-2605.	3.6	22
597	Redirection of Human Autoreactive T-Cells Upon Interaction With Dendritic Cells Modulated by TX527, an Analog of 1,25 Dihydroxyvitamin D3. Diabetes, 2002, 51, 2119-2125.	0.6	181
598	The Influence of Maternal BMI and Age in Twin Pregnancies on Insulin Resistance in the Offspring. Diabetes Care, 2002, 25, 2191-2196.	8.6	18
599	The Incidence of Type 1 Diabetes in the Age Group 0-39 Years Has Not Increased in Antwerp (Belgium) Between 1989 and 2000: Evidence for earlier disease manifestation. Diabetes Care, 2002, 25, 840-846.	8.6	122
600	1,25-dihydroxycholecalciferol: endocrinology meets the immune system. Proceedings of the Nutrition Society, 2002, 61, 375-380.	1.0	26
601	Seasonality of birth in patients with type 1 diabetes. Lancet, The, 2002, 359, 1248.	13.7	27
602	Combined use of FTY720 and cyclosporine A prevents chronic allograft vasculopathy. Transplantation Proceedings, 2002, 34, 748-749.	0.6	3
603	The coming of age of 1,25-dihydroxyvitamin D3 analogs as immunomodulatory agents. Trends in Molecular Medicine, 2002, 8, 174-179.	6.7	424
604	An uncommon tumor in a renal graft recipient: A diagnostic and therapeutic challenge. American Journal of Kidney Diseases, 2002, 40, e21.1-e21.6.	1.9	1
605	Blockade of CTLA-4 enhances allergic sensitization and eosinophilic airway inflammation in genetically predisposed mice. European Journal of Immunology, 2002, 32, 585-594.	2.9	81
606	Changes in antioxidant expression and harpin-induced hypersensitive response in a Nicotiana sylvestris mitochondrial mutant. Plant Physiology and Biochemistry, 2002, 40, 561-566.	5.8	18
607	Treatment of autoimmune diabetes recurrence in non-obese diabetic mice by mouse interferon-Î ² in combination with an analogue of 1α ,25-dihydroxyvitamin-D3. Clinical and Experimental Immunology, 2002, 128, 213-220.	2.6	49
608	Gender differences in the psychological adjustment to type 1 diabetes mellitus: an explorative study. Patient Education and Counseling, 2002, 48, 139-145.	2.2	50
609	IA-2 autoantibodies predict impending Type I diabetes in siblings of patients. Diabetologia, 2002, 45, 1658-1666.	6.3	76
610	A View on Beta Cell Transplantation in Diabetes. Annals of the New York Academy of Sciences, 2002, 958, 69-76.	3.8	30
611	Seksuele problemen bij vrouwen met diabetes mellitus type 1 en bij een vergelijkbare controlegroep. Tijdschrift Voor Geneeskunde, 2002, 58, 1589-1598.	0.0	0
612	Identification and immune regulation of 25-hydroxyvitamin D-1- <i>α</i> -hydroxylase in murine macrophages. Clinical and Experimental Immunology, 2001, 120, 139-146.	2.6	240

#	Article	IF	CITATIONS
613	A Medicago truncatula Homoglutathione Synthetase Is Derived from Glutathione Synthetase by Gene Duplication. Plant Physiology, 2001, 126, 1706-1715.	4.8	62
614	An Overview of Real-Time Quantitative PCR: Applications to Quantify Cytokine Gene Expression. Methods, 2001, 25, 386-401.	3.8	1,150
615	Gonadotropin level abnormalities in women with cyclic mastalgia. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2001, 94, 92-96.	1.1	3
616	Addition of steroids blocks the tolerogenic potential of donor-specific blood transfusion. Transplantation Proceedings, 2001, 33, 375-376.	0.6	18
617	Intestinal allografts delay rejection and prolong survival of combined donor-specific and third party solid organ transplants. Transplantation Proceedings, 2001, 33, 1550-1552.	0.6	2
618	Current limitations of islet transplantation. Transplantation Proceedings, 2001, 33, 1707-1708.	0.6	8
619	Leflunomide and its analogue X920715 synergize with cyclosporin A in preventing early graft failure and delaying graft rejection of xenogeneic islets in nonobese diabetic mice. Transplantation Proceedings, 2001, 33, 2094-2095.	0.6	3
620	Immunomodulatory properties of a 1,25(OH)2 vitamin D3 analog combined with IFNÎ ² in an animal model of syngeneic islet transplantation. Transplantation Proceedings, 2001, 33, 2319.	0.6	11
621	A combination of KH1060, a vitamin D3 analogue, and cyclosporin prevents early graft failure and prolongs graft survival of xenogeneic islets in nonobese diabetic mice. Transplantation Proceedings, 2001, 33, 2365.	0.6	24
622	TRANSFORMING GROWTH FACTOR-?? INHIBITS LYMPHOKINE ACTIVATED KILLER CYTOTOXICITY OF BONE MARROW CELLS. Transplantation, 2001, 71, 292-299.	1.0	27
623	Male-to-female excess in diabetes diagnosed in early adulthood is not specific for the immune-mediated form nor is it HLA-DQ restricted: possible relation to increased body mass index. Diabetologia, 2001, 44, 40-47.	6.3	53
624	Monocyte chemoattractant protein-1 is expressed in pancreatic islets from prediabetic NOD mice and in interleukin-1β-exposed human and rat islet cells. Diabetologia, 2001, 44, 325-332.	6.3	144
625	Dual role of interferon-Î ³ signalling pathway in sensitivity of pancreatic beta cells to immune destruction. Diabetologia, 2001, 44, 567-574.	6.3	27
626	Role of interleukin-12 in the induction of mucosal inflammation and abrogation of regulatory T cell function in chronic experimental colitis. European Journal of Immunology, 2001, 31, 1550-1560.	2.9	56
627	In Vitro and In Vivo Analysis of the Immune System of Vitamin D Receptor Knockout Mice. Journal of Bone and Mineral Research, 2001, 16, 2057-2065.	2.8	145
628	Sexual Rehabilitation for Men with Spinal Cord Injury: Preliminary Report on a Behavioral Strategy. Sexuality and Disability, 2001, 19, 149-157.	1.0	15
629	Muscle fibre membrane instability in a young boy with an insulinoma. Clinical Endocrinology, 2001, 55, 559-561.	2.4	0
630	Muscle fibre membrane instability in a young boy with an insulinoma. Clinical Endocrinology, 2001, 55, 559-561.	2.4	0

#	Article	IF	CITATIONS
631	Posttransplantation Diabetes Mellitus in FK-506-Treated Renal Transplant Recipients: Analysis of Incidence and Risk Factors. Transplantation 2001; 72: 1655 Transplantation, 2001, 72, 1593-1594.	1.0	4
632	POSTTRANSPLANTATION DIABETES MELLITUS IN FK-506-TREATED RENAL TRANSPLANT RECIPIENTS: ANALYSIS OF INCIDENCE AND RISK FACTORS. Transplantation, 2001, 72, 1655-1661.	1.0	128
633	Islet xenograft destruction in the hu-PBL-severe combined immunodeficient (SCID) mouse necessitates anti-CD3 preactivation of human immune cells. Clinical and Experimental Immunology, 2000, 121, 557-565.	2.6	13
634	Streptococcal wall component OK432 restores sensitivity of non-obese diabetic (NOD) thymocytes to apoptotic signals. Diabetologia, 2000, 43, 1302-1308.	6.3	7
635	Use of an islet cell antibody assay to identify type 1 diabetic patients with rapid decrease in C-peptide levels after clinical onset. Belgian Diabetes Registry. Diabetes Care, 2000, 23, 1072-1078.	8.6	52
636	Prevention of Experimental Colitis in SCID Mice Reconstituted with CD45RBhigh CD4+ T Cells by Blocking the CD40-CD154 Interactions. Journal of Immunology, 2000, 164, 6005-6014.	0.8	118
637	Deficient Mineralization of Intramembranous Bone in Vitamin D-24-Hydroxylase-Ablated Mice Is Due to Elevated 1,25-Dihydroxyvitamin D and Not to the Absence of 24,25-Dihydroxyvitamin D*. Endocrinology, 2000, 141, 2658-2666.	2.8	257
638	Recent developments in the use of vitamin D analogues. Expert Opinion on Investigational Drugs, 2000, 9, 443-455.	4.1	44
639	Early graft failure of xenogeneic islets in NOD mice is accompanied by high levels of interleukin-1 and low levels of transforming growth factor-beta mRNA in the grafts. Diabetes, 2000, 49, 1992-1997.	0.6	51
640	1alpha,25-dihydroxyvitamin D3 induces an autoantigen-specific T-helper 1/T-helper 2 immune shift in NOD mice immunized with GAD65 (p524-543). Diabetes, 2000, 49, 1301-1307.	0.6	163
641	Conceptually New 20-epi-22-Oxa Sulfone Analogues of the Hormone 1α,25-Dihydroxyvitamin D3: Synthesis and Biological Evaluation. Journal of Medicinal Chemistry, 2000, 43, 3581-3586.	6.4	24
642	ANALOGS OF 1,25-DIHYDROXYVITAMIN D 3 AS DOSE-REDUCING AGENTS FOR CLASSICAL IMMUNOSUPPRESSANTS12. Transplantation, 2000, 69, 1932-1942.	1.0	107
643	Oxidative stress occurs during soybean nodule senescence. Planta, 1999, 208, 73-79.	3.2	99
644	Organization and expression of mouse nm23-M1 gene. Comparison with nm23-M2 expression. Gene, 1999, 236, 221-230.	2.2	15
645	Stable β-phosphorylated cyclic aminoxyl radicals in SDS micelles. Journal of the Chemical Society Perkin Transactions II, 1999, , 2777-2781.	0.9	12
646	Splenic Dendritic Cells From the Non-obese Diabetic Mouse Induce a Prolonged Proliferation of Syngeneic T Cells. A Role for an Impaired Apoptosis of NOD T cells?. Journal of Autoimmunity, 1999, 13, 373-382.	6.5	30
647	QUANTIFICATION OF MURINE CYTOKINE mRNAs USING REAL TIME QUANTITATIVE REVERSE TRANSCRIPTASE PCR. Cytokine, 1999, 11, 305-312.	3.2	531
648	Nonclassical Effects of 11±,25-Dihydroxyvitamin D ₃ and Its Analogs. Mineral and Electrolyte Metabolism, 1999, 25, 345-348.	1.1	7

#	Article	IF	CITATIONS
649	Insulin Lispro (Humalog®) In The Treatment Of Diabetes Mellitus: Overview Of Belgian Clinical Data From Global Studies. Acta Clinica Belgica, 1999, 54, 241-245.	1.2	2
650	Characterisation of a cDNA Encoding Î ³ -Glutamylcysteine Synthetase inMedicago truncatula. Free Radical Research, 1999, 31, 213-218.	3.3	9
651	Arrays of Interacting Magnetic Dots and Wires: Static and Dynamic Properties. Journal of the Magnetics Society of Japan, 1999, 23, 670-675.	0.4	12
652	XENOGENEIC ISLET GRAFT DESTRUCTION IN THE HUMAN SCID MOUSE MODEL CAN ONLY BE ACHIEVED BY HUMAN PREACTIVATED IMMUNE CELLS Transplantation, 1999, 67, S138.	1.0	0
653	COOPERATIVITY OF A 1,25-DIHYDROXYVITAMIN D3 NON-STEROIDAL E-RING ANALOG WITH CLASSICAL IMMUNOSUPPRESSANTS Transplantation, 1999, 67, S64.	1.0	0
654	PRIMARY NONFUNCTION OF ISLET XENOGRAFTS IN SPONTANEOUSLY DIABETIC AUTOIMMUNE NOD MICE: CORRELATION WITH ELEVATED NON-T CELL CYTOKINES AND FASL EXPRESSION IN THE GRAFTS Transplantation, 1999, 67, S137.	1.0	0
655	IL-18 inhibits diabetes development in nonobese diabetic mice by counterregulation of Th1-dependent destructive insulitis. Journal of Immunology, 1999, 163, 1230-6.	0.8	47
656	The role of interferon regulatory factor-1 in cytokine-induced mRNA expression and cell death in murine pancreatic beta-cells. European Cytokine Network, 1999, 10, 403-12.	2.0	35
657	Glykemieregeling bij diabetes mellitus type 2. Tijdschrift Voor Geneeskunde, 1999, 55, 789-792.	0.0	0
658	Insulineanalogons. Tijdschrift Voor Geneeskunde, 1999, 55, 793-796.	0.0	0
659	Nuchtere glykemie bij glucosetolerantietest. Tijdschrift Voor Geneeskunde, 1999, 55, 1342-1342.	0.0	0
660	Tissue-specific expression of genes encoding isoforms of the mitochondrial ATPase beta subunit in Nicotiana sylvestris. Plant Molecular Biology, 1998, 38, 885-888.	3.9	16
661	Direct Detection of Radicals in Intact Soybean Nodules: Presence of Nitric Oxide-Leghemoglobin Complexes. Free Radical Biology and Medicine, 1998, 24, 1242-1249.	2.9	121
662	Diabetes mellitus and female sexuality: a review of 25 years' research. , 1998, 15, 809-815.		112
663	1,25-Dihydroxyvitamin D3 restores sensitivity to cyclophosphamide-induced apoptosis in non-obese diabetic (NOD) mice and protects against diabetes. Clinical and Experimental Immunology, 1998, 112, 181-187.	2.6	73
664	Prevention of Diabetes Recurrence After Syngeneic Islet Transplantation in NOD Mice by Analogues of 1,25(OH)2D3 in Combination With Cyclosporin A: Mechanism of Action Involves an Immune Shift From TH1 to TH2. Transplantation Proceedings, 1998, 30, 541.	0.6	18
665	Prevention of islet graft destruction in diabetic mice and rats by temporary Anti-IL-2 receptor therapy: comparison of different strategies. Transplantation Proceedings, 1998, 30, 4140-4142.	0.6	1
666	Lateral Quantization of Spin Waves in Micron Size Magnetic Wires. Physical Review Letters, 1998, 81, 3968-3971.	7.8	202

Chantal Mathieu

#	Article	IF	CITATIONS
667	Sex difference in resistance to dexamethasone-induced apoptosis in NOD mice: treatment with 1,25(OH)2D3 restores defect. Diabetes, 1998, 47, 1033-1037.	0.6	45
668	Prevention of Type I Diabetes in Nonobese Diabetic Mice by Late Intervention with Nonhypercalcemic Analogs of 1,25-Dihydroxyvitamin D3 in Combination with a Short Induction Course of Cyclosporin A*. Endocrinology, 1998, 139, 95-102.	2.8	112
669	Correlation between structure and magnetic anisotropies of Co on Cu(110). Physical Review B, 1998, 57, 5870-5878.	3.2	42
670	Recent developments in the use of vitamin D analogues. Current Opinion in Nephrology and Hypertension, 1998, 7, 397-404.	2.0	25
671	Diabetes mellitus and female sexuality: a review of 25 years' research. Diabetic Medicine, 1998, 15, 809-815.	2.3	2
672	PREVENTION OF AUTOIMMUNE DESTRUCTION OF SYNGENEIC ISLET GRAFTS IN SPONTANEOUSLY DIABETIC NONOBESE DIABETIC MICE BY A COMBINATION OF AVITAMIN D3 ANALOG AND CYCLOSPORINE1. Transplantation, 1998, 65, 1225-1232.	1.0	96
673	Prevention of Type I Diabetes in Nonobese Diabetic Mice by Late Intervention with Nonhypercalcemic Analogs of 1,25-Dihydroxyvitamin D3 in Combination with a Short Induction Course of Cyclosporin A. Endocrinology, 1998, 139, 95-102.	2.8	34
674	Redevelopment of the tolerance to pancreatic B-cells in BB rats. Experimental and Clinical Endocrinology and Diabetes, 1997, 105, 94-94.	1.2	0
675	1,25(OH)2D3 protects against cyclophosphamide-induced diabetes and enhances apoptosis induced by cyclophosphamide. Experimental and Clinical Endocrinology and Diabetes, 1997, 105, 28-29.	1.2	17
676	Absence of Synproportionation Between Oxy and Ferryl Leghemoglobin. Free Radical Research, 1997, 27, 165-171.	3.3	3
677	Effects of a Mechanical Stimulation on Localization of Annexin-Like Proteins in Bryonia dioica Internodes. Plant Physiology, 1997, 114, 981-988.	4.8	44
678	Reduction of β-phosphorylated cyclic aminoxyl radicals by flavins: an EPR kinetic study â€. Journal of the Chemical Society Perkin Transactions II, 1997, , 2501-2506.	0.9	8
679	Anisotropic magnetic coupling of permalloy micron dots forming a square lattice. Applied Physics Letters, 1997, 70, 2912-2914.	3.3	114
680	Differentiation induction of HL60 cells by 1,25(OH)2D3, all trans retinoic acid, rTGF-β2 and their combinations. Journal of Steroid Biochemistry and Molecular Biology, 1997, 60, 87-97.	2.5	18
681	Brillouin light scattering investigations of structured permalloy films. Journal of Applied Physics, 1997, 81, 4993-4995.	2.5	52
682	1,25-Dihydroxyvitamin D3 reduces MHC antigen expression on pancreatic beta-cells in vitro. Transplantation Proceedings, 1997, 29, 2156-2157.	0.6	30
683	Synergism between sirolimus and 1,25-dihydroxyvitamin D3 in vitro and in vivo. Journal of Neuroimmunology, 1997, 79, 138-147.	2.3	48
684	The leukemia-associated gene MDS1/EVI1 is a new type of GATA-binding transactivator. Leukemia, 1997, 11, 352-358.	7.2	98

#	Article	IF	CITATIONS
685	Static and dynamic properties of patterned magnetic permalloy films. Journal of Magnetism and Magnetic Materials, 1997, 175, 10-15.	2.3	24
686	β-Phosphorylated Nitroxides in the Pyrrolidine Series: Reduction by Ascorbate. Free Radical Biology and Medicine, 1997, 22, 803-806.	2.9	22
687	Structure and specific expression of a Nicotiana sylvestris putative amino-acid transporter gene in mature and in vitro germinating pollen. Plant Molecular Biology, 1997, 35, 855-864.	3.9	18
688	Insulin-dependent diabetes mellitus: ethical considerations for prevention trials. Diabetes/metabolism Reviews, 1997, 13, 201-206.	0.3	0
689	Protection against autoimmune diabetes in mixed bone marrow chimeras: mechanisms involved. Journal of Immunology, 1997, 158, 1453-7.	0.8	22
690	Combination of Vitamin D Analogues and Immunosuppressants. BioDrugs, 1996, 6, 465-478.	0.7	11
691	Leghemoglobin-derived Radicals. Journal of Biological Chemistry, 1996, 271, 32557-32562.	3.4	27
692	Prevention of type I diabetes by late intervention with nonhypercalcemic analogues of vitamin D3 in combination with cyclosporin A. Transplantation Proceedings, 1996, 28, 3095.	0.6	11
693	Immunomodulatory effects of 1,25-dihydroxyvitamin D3. Current Opinion in Nephrology and Hypertension, 1995, 4, 313-318.	2.0	77
694	Prevention of type I diabetes in NOD mice by nonhypercalcemic doses of a new structural analog of 1,25-dihydroxyvitamin D3, KH1060 Endocrinology, 1995, 136, 866-872.	2.8	154
695	Paracrine role for calcitriol in the immune system and skin creates new therapeutic possibilities for vitamin D analogs. European Journal of Endocrinology, 1995, 133, 7-16.	3.7	65
696	Deletion of the last two exons of the mitochondrialnad7 gene results in lack of the NAD7 polypeptide in aNicotiana sylvestris CMS mutant. Molecular Genetics and Genomics, 1995, 248, 79-88.	2.4	92
697	Changes in plasma membrane fluidity of Bryonia dioica internodes during thigmomorphogenesis. Biochimica Et Biophysica Acta - Biomembranes, 1995, 1235, 249-255.	2.6	6
698	Non-hypercalcemic pharmacological aspects of vitamin D analogs. Biochemical Pharmacology, 1995, 50, 577-583.	4.4	45
699	Differentiation induction of human leukemia cells (HL60) by a combination of 1,25-dihydroxyvitamin D3 and retinoic acid (all trans or 9-cis). Journal of Steroid Biochemistry and Molecular Biology, 1995, 53, 431-441.	2.5	25
700	Prevention of type I diabetes in NOD mice by nonhypercalcemic doses of a new structural analog of 1,25-dihydroxyvitamin D3, KH1060. Endocrinology, 1995, 136, 866-872.	2.8	49
701	Induction of mixed bone marrow chimerism as potential therapy for autoimmune (type I) diabetes: experience in the NOD model. Transplantation Proceedings, 1995, 27, 640-1.	0.6	10
702	Restriction of interferon gamma responsiveness and basal expression of the myeloid human Fc gamma R1b gene is mediated by a functional PU.1 site and a transcription initiator consensus Journal of Experimental Medicine, 1994, 179, 1985-1996.	8.5	116

#	Article	IF	CITATIONS
703	Prevention of autoimmune diabetes in NOD mice by 1,25 dihydroxyvitamin D3. Diabetologia, 1994, 37, 552-558.	6.3	415
704	Prevention of autoimmune diabetes in NOD mice by 1,25 dihydroxyvitamin D 3. Diabetologia, 1994, 37, 552-558.	6.3	25
705	SPONTANEOUS REESTABLISHMENT OF SELF-TOLERANCE IN BB/PFD RATS. Transplantation, 1994, 58, 349-354.	1.0	12
706	Light Scattering Investigations of Magnetic Anisotropies in Ultrathin Epitaxial Co Films. Acta Physica Polonica A, 1994, 85, 179-193.	0.5	15
707	Potential role of 1,25(OH)2 vitamin D3 as a dose-reducing agent for cyclosporine and FK 506. Transplantation Proceedings, 1994, 26, 3130.	0.6	16
708	Activated form of vitamin D [1,25(OH)2D3] and its analogs are dose-reducing agents for cyclosporine in vitro and in vivo. Transplantation Proceedings, 1994, 26, 3048-9.	0.6	15
709	Prevention of autoimmune destruction of transplanted islets in spontaneously diabetic NOD mice by KH1060, a 20-epi analog of vitamin D: synergy with cyclosporine. Transplantation Proceedings, 1994, 26, 3128-9.	0.6	25
710	Spontaneous reestablishment of self-tolerance in BB/Pfd rats. Transplantation, 1994, 58, 349-54.	1.0	4
711	Diabetic BB/PFD rats reject MHC incompatible islet grafts, but do not destroy MHC compatible islet grafts. Transplantation Proceedings, 1994, 26, 718-9.	0.6	0
712	SPONTANEOUS REESTABLISHMENT OF SELF-TOLERANCE IN BB/PFD RATS. Transplantation, 1994, 58, 349-354.	1.0	0
713	Lack of Disease Recurrence in Diabetic BB/PFD Rats After Syngeneic Islet Transplantation. Autoimmunity, 1993, 15, 107-112.	2.6	9
714	Protection against autoimmune diabetes by induction of mixed bone marrow chimerism. Transplantation Proceedings, 1993, 25, 1266-7.	0.6	4
715	1,25-Dihydroxyvitamin D3 Prevents Insulitis in NOD Mice. Diabetes, 1992, 41, 1491-1495.	0.6	217
716	1,25-Dihydroxyvitamin D3 prevents insulitis in NOD mice. Diabetes, 1992, 41, 1491-1495.	0.6	65
717	Regeneration of cytoplasmic male sterile protoclones of Nicotiana sylvestris with mitochondrial variations. Current Genetics, 1988, 13, 261-266.	1.7	74
718	High Serum Vitamin D Concentrations, Induced via Diet, Trigger Immune and Intestinal Microbiota Alterations Leading to Type 1 Diabetes Protection in NOD Mice. Frontiers in Immunology, 0, 13, .	4.8	6